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ABSTRACT 
Vascular endothelial growth factor (VEGF) family is a group of structurally 
related peptides important in controlling vascular development and functions. We 
have previously demonstrated the expression of VEGF-A and its receptors (VEGFR-1 
and VEGFR-2) in the testis. This study aims at determining whether other members 
of VEGF family are also present, thus providing the basis for further understanding 
their role in the vascular control of the testis. Hormonal regulation of these members 
is also examined by injection of single dose of human chorionic gonadotrophin (hCG) 
to adult rats. 
Using RT-PCR, mRNA of all VEGF family members were shown to be 
expressed in rat testes, primary Leydig and Sertoli cells, and testicular cell lines from 
rat (LC540, R2C) and mouse (MLTC-1, TM3, TM4). Western immunoblotting of 
tissue and cell lysates revealed positive bands (27 kDa, 21 kDa and 15 kDa) of 
VEGF-A,88, VEGF-Ai64 and VEGF-A120； and bands (35 k D a and 24 kDa) of 
VEGF-B186 and VEGF-B167. For VEGF-C, positive band was identified at 27 kDa, 
VEGF-D at 46，37，23 and 16 kDa and PIGF (placenta growth factor) at 27 kDa. 
Variations on signal intensity of protein bands were observed in different samples and 
these could be related to their relative abundance and levels of processing in different 
cell types. Immunostaining showed strong immunoreactivity in Leydig cells, and 
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weak in Sertoli cells and vascular smooth muscle cells. Following the destruction of 
Leydig cells by ethane dimethane sulphonate (EDS) treatment, most 
immunoreactivity in the testicular interstitium disappeared and resulted in decreases 
in the levels of VEGF-Aim and VEGF-Ano isoforms, VEGF-B186 and VEGF-B167 
isoforms，but increases in the levels of VEGF-D (mRNA and 16 kDa isoform) and 
PIGR Chronic Leydig cell suppression by an eight-week treatment with exogenous 
testosterone released from subcutaneous silastic implants showed similar effect to 
EDS treatment on the expression of VEGF-Aim isoform. A single subcutaneous 
injection of 100 lU hCG was shown to increase the expression of VEGF-Aim in testes 
of normal rats and those receiving testosterone implants. This was also accompanied 
by a return ofVEGF immunoreactivity in Leydig cells. 
In conclusion, expression of various new VEGF family members was 
demonstrated in the testis (mainly found in Leydig cells and Sertoli cells). Leydig 
cell was demonstrated to be a major source of VEGF-A164 and VEGF-Ai20 isoforms, 
VEGF-B186 and VEGF-Bi67 isoforms. Expression of V E G F - D ( m R N A and 16 kDa 
isoform) and PIGF was demonstrated to be androgen repressible. Besides, 
expression of VEGF-A164 was demonstrated to be hormonally regulated by hCG. 
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摘 要 
血管內皮生長素（vascular endothelial growth factor, VEGF)家庭是一群 
結構相似的縮氣酸，對血管生長及其功能有著重要影響。我們以往已經證實血管 
內皮生長素甲型（VEGF-A)及其受體一型和二型（VEGF receptor, VEGFR-1和 
VEGFR-2)是存在於睾九中。是項硏究旨在測定是否有其他的血管內皮生長素家 
庭成員存在，以致提供基礎來認識睾九中血管生長的控制機制。我們也會注射人 
械毛膜促性腺激素(human chorionic gonadotrophin, hCG)到成年大白鼠來考察 
各血管內皮生長素家庭成員的荷爾蒙控制機制。 
我們利用逆轉腺-聚合晦連鎖反應（reverse transcriptase-polymerase chain 
reaction)錄得所有的血管內皮生長素家庭成員的信使核糖核酸（mRNA)，都能 












維管平滑肌細月包(vascular smooth muscle cells)貝U有較弱的信號。以乙院1，2 — 
甲院磺酸驢破壞睾九中的萊迪希氏細胞後，造成大部分的免疫染色法信號於睾九 
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1. Introduction 
L1 General review of angiogenesis 
Vasculogenesis and angiogenesis are the fundamental processes by which new 
blood vessels are formed (Carmeliet, 2000; Risau, 1997; Risau & Flamme, 1995; 
Vailhe et al., 2001). Vasculogenesis is defined as the differentiation of precursor cell, 
angioblasts, into endothelial cells and the de novo formation of a primitive vascular 
network, whereas angiogenesis is defined as the growth of new capillaries from 
pre-existing blood vessels (Risau, 1997; Vailhe et al., 2001). 
While vasculogenesis is mainly found in early embryogenesis，angiogenesis 
occurs not only in embryos but also is an important component of tissue growth and 
development during postnatal life. However in adults, angiogenesis rarely occurs 
under physiological conditions except in the female reproductive system where it 
forms an integral part of follicular development, corpus luteum formation, repair of 
the endometrium during the menstrual cycle, formation of the placenta and 
development of the breast during pregnancy. Angiogenesis in adults is most 
commonly associated with pathological conditions such as wound healing, 
inflammation, diabetic retinopathy, psoriasis, rheumatoid arthritis, and solid tumor 
growth (Breier et al., 1997; Edward et al, 2001; Folkman, 1995; Pepper，1997; Vailhe 
et al,，2001) 
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1.2 Vascular endothelial growth factors (VEGFs) 
Vascular endothelial growth factors (VEGFs) comprise a group of structurally 
and functionally related growth factors that modulate many important physiological 
functions of endothelial cells. Currently, five different mammalian VEGFs 
(VEGF-A, PIGF, VEGF-B, VEGF-C and VEGF-D) have been identified and they all 
show unique temporal and spatial expression patterns, receptor specificity and 
function (Li & Eriksson，2001). 
The VEGF family members are secreted dimeric glycoproteins, all of which 
contain the characteristic regularly-spaced eight cysteine residues in the VEGF 
homology domain (Fig. 1.1). These eight invariant cysteine residues are shown to be 
involved in inter- and intramolecular disulfide bonds in several of these dimeric 
growth factors (Li & Eriksson, 2001; Veikkola & Alitalo, 1999). 
The VEGFs play pivotal roles in the formation of the vascular system during 
embryonic development, in the regulation of capillary growth in normal and 
pathological conditions in adults, and in the maintenance of the normal vasculature 
(Li & Eriksson，2001; Olofsson et al.，1999). 
1.2.1 VEGF-A 
The most potent and well-studied angiogenic factor is vascular endothelial 
growth factor A (VEGF-A) which was discovered more than a decade ago (Aase， 
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2001; Li & Eriksson, 2001). The gene encoding human VEGF-A produces six 
different transcripts by alternative splicing of the eight exons in the mRNA, 
VEGF-Aiio, VEGF-A,21, VEGF-Aus, VEGF-A165, VEGF-Ai39 and VEGF-A206 
(Houck et al., 1991; Lei et al., 1998; Leung et ai, 1989; Poltorak et al, 1997). On 
the other hand, four variants from the mouse homologue have been found, VEGF-Ai 20, 
VEGF-A144, VEGF-Ai64 and VEGF-AI88 (Shima et al” 1996; Sugihara et al., 1998). 
The biologically active molecules are glycosylated disulphide-linked dimers, 
which display different biological properties. For example, the shortest isoforms, 
VEGF-Au5 and VEGF-A120/121 are freely secreted whereas the others are sequestered 
on the cell surface or the extracellular matrix due to binding to heparin sulfate 
proteoglycans (Poltorak et al., 2000; Sugihara et al., 1998). The predominant forms 
of VEGF-A are VEGF-Ai20/121, VEGF-Ai64/i65 and VEGF-Ai88/189, whereas the others 
are comparatively rare (Robinson & Stringer, 2001). VEGF-A mediates its functions 
by binding and activating receptors located on the cell surface, VEGF receptor-1 
(VEGFR-1/ flt-1), VEGFR-2 (flk-l/KDR) and neuropilin-1 and -2 (NP-1 and -2) 
(Neufeld et al.’ 1999) (Fig. 1.2). 
VEGF-A is recognized as a major hypoxia-inducible growth factor for vascular 
endothelial cells and it is upregulated under hypoxic conditions and downregulated 
under hyperoxic conditions (Alon et al., 1995; Shweiki et al., 1992). Studies have 
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also indicated that VEGF is hormonally-regulated by steroid hormones (Laitinen et aL, 
1997; Neulen et al.’ 1995，1998; Ruohola et al., 1999). 
1.2.2 PIGF 
The second growth factor in the VEGF family is called placenta growth factor 
(PIGF) because it was originally isolated from a human placenta cDNA library (Aase, 
2001; Maglione et al.’ 1991). It is about 50% homologous to VEGF-A (Maglione et 
a/.，1991). Similar to VEGF-A, PIGF is a glycosylated, secreted disulphide-linked 
dimer. In human, three PIGF isoforms have been reported and they are formed from 
alternative splicing of PIGF gene, PlGF-1 (PlGFui)，PlGF-2 (PIGF,52) and PlGF-3 
(PIGF221) (Cao et al., 1997; Hauser & Weich，1993; Maglione et al., 1993). Only 
PlGF-2 binds heparin with high affinity suggesting that this isoform is sequestered on 
the cell surface/ extracellular matrix (Hauser & Weich，1993), while the other two 
isoforms are freely secreted. In rodents, only PlGF-2 homologue has been found 
with a native peptide of 158 amino acid (AA) residues and a mature peptide (after 
removal of signal sequence) of 135 AA (DiPalma et al.’ 1996; DiSalvo et al, 1995). 
All variants of PIGF bind VEGFR-1, but only the heparin binding PlGF-2 bind NP-1 
(Migdal et al., 1998; Park et al, 1994). None of the isoforms bind VEGFR-2 (Park 
a/., 1994). 
PIGF overlaps in the expression with VEGF-A both in normal tissues, and in 
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many tumours. In fact naturally existing heterodimers of PIGF/VEGF were purified 
from a rat glioma cell line (DiSalvo et al., 1995). Later, recombinant heterodimers 
were also purified and shown to induce binding to VEGFR-2 (Cao et al., 1996). In 
contrast to VEGF-A，PIGF has been shown to be downregulated under hypoxic 
conditions (Gleadle et al., 1995). 
1.2.3 VEGF-B 
VEGF-B or VEGF-related factor (VRF) was discovered in 1996 (Olofsson et al., 
1996a). It is closely related to VEGF-A, with a homology of about 43% (Olofsson 
et al” 1996a). The mouse and human VEGF-B genes are almost identical and are 
composed of seven exons (Olofsson et al., 1996b). There are two isoforms of 
V E G F - B , VEGF-Bi67 and VEGF-BIGE, produced by alternative splicing of the 
acceptor site in exon 6. Difference in the carboxy-terminals of the two isoforms 
affects their biochemical and biological features. The shorter variant contains a 
cell-associating, heparin-binding carboxy-terminus resembling that of VEGF-A, 
whereas the carboxy-terminal region of the longer variant is hydrophobic and freely 
secreted (Aase，2001; Olofsson et al., 1996a，b) (Fig. 1.1). 
VEGF-B shares many features of VEGF-A, such as its disulphide-linked 
dimerisation and binding to the VEGFR-1 and NP-1, but unlike VEGF-A, VEGF-B is 
not affected by hypoxia and hormone and does not bind VEGFR-2 (Enholm et al., 
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1997; Laitinen et al., 1997; Makinen et al” 1999; Olofsson et al” 1998). 
1.2.4 VEGF-C and VEGF-D 
VEGF-C and VEGF-D differ in many aspects from VEGF-A, PIGF and VEGF-B. 
They are mainly thought of as being important mainly for lymphatic endothelium and 
lymphangiogenesis and constitute a subgroup based on their unique amino- and 
carboxy-terminal regions flanking the VEGF homology domain (Fig. 1.1) (Aase, 2001; 
Joukov et al” 1996; Joukov et al., 1997b; Lee et al., 1996; Orlandini et al” 1996; 
Yamada et al., 1997). Their carboxy-terminal regions contain a repetitive pattern of 
cysteine residues with homology to a component in the silk produced by the silk 
larvae, Chironomus tentans (Chilov et al； 1997). VEGF-C and VEGF-D are 
synthesised as pre-proproteins where the carboxy-terminal parts are cleaved off upon 
secretion, but remain bound via disulphide bonds. The proproteins bind to 
VEGFR-3 (flt-4), a receptor exclusively expressed on lymphatic endothelium, 
whereas binding to VEGFR-2 requires proteolytic processing of the amino-terminal 
regions (Joukov et al., 1997a; Kukk et al., 1996). 
Unlike VEGF-A, the expression of VEGF-C does not appear to be regulated by 
hypoxia (Enholm et al., 1997)，but is increased in response to proinflammatory 
cytokines suggesting a role in inflammatory responses (Ristimaki et al” 1998). It 
has also been known that VEGF-C is hormonally down-regulated by steroid 
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hormones (Laitinen et al” 1997). VEGF-C is likely to play a dual role, both as an 
angiogenic and lymphangiogenic growth factor; depending on the spatio-temporal 
expression of its receptors (Cao et al” 1998). VEGF-D has been shown to be 
angiogenic as well as serving as a mitogen for both fibroblasts and endothelial cells, 
although it is less potent than VEGF-A (Achen et al” 1998; Marconcini et al., 1999; 
Orlandini et al, 1996). Interestingly, mouse VEGF-D does not bind mouse 
VEGFR-2, suggesting that the biological functions of VEGF-D differ in mouse and 
man，and that VEGF-D interaction with VEGFR-2 is not crucial for normal 
development (Baldwin et al, 2001). 
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Fig. 1.1 Schematic illustration of the domain structures of the currently known 
members of the VEGF family, including the novel VEGF family members, 
VEGF-B，VEGF-C and VEGF-D. The different domain structures include the VEGF 
homology domain (in green), the C-terminal regions containing the basic 
heparin-binding domains in some spliced isoforms of VEGF, PIGF and VEGF-B (in 
dark blue), the unique C-terminal domain in VEGF-B 186 (in red), the N-terminal 
propeptide domains (in light blue), and silk domain-containing C-terminal 
propeptides in VEGF-C and D (in yellow). Note that the different domains are not 
drawn in scale. The numbers to the right refer to the number of amino acids in the 
proteins shown. (Adapted from Li & Eriksson, 2001) 
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1,3 VEGF receptors (VEGFRs) 
VEGFs exert their functions via binding to cell surface receptors and thereby 
transducing their signals into the cell (Fig. 1.2). The VEGFs bind to two different 
types of receptors, the VEGF receptors (VEGFRs) and neuropilins (NP). VEGFRs 
are receptor tyrosine kinases that consist of an extracellular domain of seven 
immunoglobulin-like (Ig) repeats, a hydrophobic transmembrane domain that anchors 
the receptor in the cell membrane, a juxtamembrane domain and a protein kinase 
domain that is split into two halves. The dimeric VEGFs bind two receptors 
simultaneously; thus forming a stable receptor dimer that becomes activated by the 
subsequent autophosphorylation, i.e. one receptor subunit phosphorylates the other 
(Aase, 2001; Veikkola & Alitalo，1999). 
1.3.1 VEGFR-1 (orflt-1) 
VEGFR-1, or flt-1 (fms-like tyrosine kinase), is the receptor for VEGF-A, 
PIGF and VEGF-B (Aase, 2001; de Vries et al” 1992; Olofsson et al.’ 1998; Park et 
al., 1994; Shibuya et al., 1990). Just as many of the VEGFs, the VEGFR-1 gene 
gives rise to two different isoforms; a full-length receptor and an extracellular form 
called soluble VEGFR-1 (sVEGFR-1) (Kendall et al., 1996). This soluble receptor 
is abundantly expressed in the placenta and can form heterodimers with VEGFR-2 
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(Kendall et al., 1996). 
The kinase activity of VEGFR-1 is much lower than that of other fins tyrosine 
kinases and the receptors for the PDGFs (Sawano et al” 1996; Shibuya et al, 1999). 
The weak kinase activity could be a result of unstable VEGFR dimers, tight regulation 
by tyrosine phosphatases or few phosphorylation sites (Shibuya et al.’ 1999). 
One interesting fact with VEGFR-1 is that the catalytic cytoplasmic domain is 
not essential for proper cardiovascular development, thus signalling from VEGFR-1 
seems to be insignificant during embryogenesis and the role of VEGFR-1 might be 
that of a sink, where excess VEGF-A is drained (Hiratsuka et al., 1998). However, 
VEGF-A- or PlGF-induced monocyte migration was suppressed in mice lacking the 
intracellular tyrosin kinase domain of VEGFR-1. 
1.3.2 VEGFR-2 (orflk-1) 
The second receptor was originally called KDR (kinase insert-domain containing 
receptor) for the human protein and flk-1 (fetal liver kinase 1) for the mouse 
homologue (Aase，2001; Matthews et al, 1991; Terman et al.’ 1991). VEGFR-2 
binds VEGF-A, VEGF-C and VEGF-D (Achen et al., 1998; Joukov et al； 1996; 
Terman et al.’ 1992). VEGFR-2 mRNA is first detected in presumptive mesodermal 
yolk-sac blood island progenitors and then in the primitive endothelium surrounding 
the blood islands, thus VEGFR-2 seems to play an important role during 
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vasculogenesis (Shalaby et al, 1995). The overall structure and binding properties 
are highly related to VEGFR-1 (Fuh et al, 1998; Shibuya et al” 1999). 
jn vitro studies have shown that VEGFR-1 and VEGFR-2 respond differently to 
VEGF-A stimulation. Both receptors induced cell migration, but mitogenic signals 
were only transduced via VEGFR-2 (Barleon et al., 1996; Seetharam et al, 1995; 
Soker et al.，1998; Waltenberger et al.’ 1994; Yoshida et al.’ 1996). Also, 
VEGF-A-induced vascular permeability occurs primarily via VEGFR-2 (Hiratsuka et 
al” 1998; Joukov et al., 1998). 
1.3.3 VEGFR-3 (flt-4) 
VEGFR-3 (flt-4) is a receptor for VEGF-C and VEGF-D and differs from the 
other VEGF receptors is that it has to be proteolytically processed before it can bind 
to its ligands (Aase，2001; Achen et al., 1998; Joukov et al., 1996; Pajusola et al., 
1992; Pajusola et al.’ 1994). Early in mouse development, VEGFR-3 is expressed in 
the cardinal vein and in the angioblasts of the head mesenchyme but as 
embryogenesis continues VEGFR-3 expression becomes restricted to the lymphatic 
endothelium (Kaipainen et aL, 1995). In adults, VEGFR-3 is found in the lymphatic 
endothelium of the lung, mesenterium and tonsil, while vascular endothelium is 
negative (Kaipainen et al., 1995). In spite of the documented restriction to 
lymphatic vessels, recent data show that VEGFR-3 is expressed both in the blood and 
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lymphatic vessels in the nasal mucosa of human adults and in the fenestrated 
capillaries of several organs (Partanen et al, 2000; Saaristo et al., 2000). 
In line with the angiogenic capacity of VEGF-C and VEGF-D, VEGFR-3 was 
shown to play a role in the development of the cardiovascular system before 
lymphatic vessels appear (Dumont et al.’ 1998). Vasculogenesis was not affected in 
VEGFR-3 deficient embryos, nor was sprouting angiogenesis, but VEGFR-3 
signalling was shown to be important for vascular remodelling and maturation of the 
primitive vascular network (Aase，2001; Dumont et al., 1998; Veikkola & Alitalo， 
1999). 
In human, the VEGFR-3 gene encodes two polypeptides (a long form and a short 
form) that differ at their C-terminus due to alternative splicing (Galland et al” 1993; 
Pajusola et al” 1993). The long form is the predominant form in most tissues. It is 
interesting to note that an endogenous retroviral genome appears responsible for the 
short isoform in humans, but this form is missing from mice (Hughes, 2001). 
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Fig. 1.2 Schematic illustration of the binding of VEGF family members to VEGF 
receptors 1，2 and 3. Ligand activation of the receptors induces a variety of 
effects in the receptor-expressing endothelial cells including growth, survival, 
permeability, migration and vessel remodelling. VEGFR-3 and its two ligands, 
VEGF-C and VEGF-D, are specifically involved in lymphangiogenesis while all 
VEGFs and their receptors are implicated in angiogenesis. The different 
interactions of VEGFs with soluble VEGFR-1，the co-receptor NP-1, and with 
heparan sulfate proteoglycans are not shown. (Adapted from Li & Eriksson, 
2001) 
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1.4 Hormonal regulation of VEGFs by LH/h CG 
Human chorionic gonadotrophin (hCG) is a glycoprotein hormone normally 
secreted by the placenta. However, it is structurally and biologically closely related 
to the pituitary-derived luteinizing hormone (LH), hCG binds to the same receptor 
and acts as a potent LH agonist (Gharib et al., 1990; Rulli et al” 2003). 
Evidence is accumulating to indicate that VEGF is involved in mediating 
hormonally-regulated angiogenesis. VEGF is expressed in many endocrine glands 
(e.g. thyroid, pancreas, adrenal, pituitary and testis) and hormone-responsive tissues 
like the uterus, fallopian tube, placenta and breast (Fujimoto et al.’ 1998; Gordon et 
al., 1996; Toi et al.，1995; Winther et al., 1999). 
In the ovary, Neulen et al. (1995) demonstrated that the VEGF gene expression 
in cultured luteinized granulosa cells was stimulated by LH/hCG in both time- and 
dose-dependent manner. These cells were obtained from human ovarian follicles 
around the time of ovulation when a marked increase in follicular angiogenesis occurs. 
Later，Neulen et al (1998) showed VEGF secreted from human luteinized granulosa 
cells is hCG dependent and suggested that vascularization of the corpus luteum is 
caused by hCG-induced VEGF release. Laitinen et al. (1997) demonstrated that 
primary cultures of human granulosa-luteal (GL) cells exposed to recombinant human 
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FSH (rhFSH) significantly increased the levels of VEGF mRNA, however, VEGF-C 
mRNA levels were down-regulated and VEGF-B mRNA levels seemed more or less 
unchanged. Studies also presented that VEGF protein was expressed throughout the 
luteal phase, and hence it might play a role in the cyclic growth of ovarian follicles 
and corpus luteum development and maintenance, and mediating ovarian 
angiogenesis. Furthermore the expression and secretion of VEGF were induced by 
both FSH and LH/hCG receptor-activated pathways (Geva & Jaffe，2000; Wulff et al, 
2001). 
Gonadotrophin suppression by gonadotrophin releasing hormone (GnRH) 
antagonist treatment significantly lowered the increase in VEGF mRNA levels in 
transplanted ovaries of immature rats (Dissen et al., 1994)，and this could not be 
compensated by injecting these animals with PMSG (pregnant mare serum 
gonadotrophin), suggesting the activity of LH might be more important. Finally, 
conditioned medium from gonadotrophin-treated human ovarian carcinoma cells was 
shown to be mitogenic to bovine endothelial cells and this activity could only be 
blocked by neutralizing antibodies against LH or VEGF (Schiffenbauer et al” 1997). 
Using RT-PCR, both LH and FSH were shown to produce a dose-dependent 
stimulation of VEGF expression in these cultured human ovarian cancer spheroids. 
Based on the above findings of a predominant LH effect in stimulating VEGF 
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expression in the ovary, it would be tempting to speculate that LH might have a 
similar action in the testis to upregulate VEGF expression in Leydig cells, and this 
was confirmed by a recent study demonstrated by Haggstrom Rudolfsson et al (2003) 
that testicular VEGF secretion was increased by hCG stimulation of Leydig cells and 
that VEGF, through effects mediated via VEGFR-2, regulated endothelial cell 
proliferation in the rat testis. 
LH/hCG is known to cause vascular changes in the testis. Following a single 
subcutaneous injection of 50-100 lU hCG into adult rats, vascular permeability 
increased together with an accumulation of interstitial fluid and a rise in blood flow 
(Setchell & Sharpe, 1981). The same dose of hCG (100 lU) has recently been 
shown to stimulate endothelial cell proliferation in the testicular vasculature (Au et al” 
1996; Collin & Bergh，1996)，with the maximum changes occurring at 2 days 
post-injection. The angiogenic response (Au et al., 1996; Collin & Bergh，1996) and 
the permeability increase (Setchell & Rommerts, 1985; Collin & Bergh，1996) are 
dependent on factors originating from the Leydig cells as the changes are completely 
abolished following the depletion of Leydig cells by ethane dimethane sulphonate 
treatment. This would be expected since Leydig cells represent the only cell type in 
the testis that binds LH/hCG (Mendelson et al., 1975). The Leydig cell product that 
could best fulfill such a role is VEGF as it can induce vascular hyperpermeability, 
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endothelial cell proliferation, and an increase in blood flow (Lopez et al., 1997; Ni et 
al., 1997; Tilton et al., 1999). In the view of above findings, the expression and 
regulation of VEGFs in the testis by LH/hCG are worth for further exploring. 
1.5 General review of the testis 
1.5.1 Structure and function of the testis 
The testes are oval, paired structures suspended by the spermatic cords and 
housed within the scrotum. Each testis is surrounded by a membranous capsule 
which is made up of three distinct layers, namely tunica vasculosa，tunica albuginea 
and tunica vaginalis. The testis parenchyma is structurally and functionally divided 
into two compartments - the seminiferous tubules and the intertubular tissue (or 
interstitium). Lining the seminiferous tubules is a compound epithelium consisting 
of germ cells and Sertoli cells. Production of spermatozoa occurs within these 
tubules in a process known as spermatogenesis. The interstitium contains lymphatic 
vessel, blood vessels, variable amount of connective tissues and a variety cell types 
including Leydig cells, macrophages, fibroblasts and mast cell. 
The testes serve two major functions in adults, namely the production of 
spermatozoa and the secretion of androgens, mainly testosterone. These functions 
are known to be regulated primarily by the two gonadotrophins produced by the 
anterior pituitary - follicle stimulating hormone (FSH) and luteinizing hormone (LH). 
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The release of these two hormones is in turn under the control of gonadotrophin 
releasing hormone (GnRH) produced by the hypothalamus. FSH acts specifically on 
the Sertoli cells to support the process of spermatogenesis. LH acts on the Leydig 
cells to stimulate androgen production which is needed for the development and 
maintenance of the spermatogenic process as well as the secondary sexual 
characteristics. In addition to the hypothalamic-pituitary control of testicular 
functions, there is increasing evidence to indicate that hormone actions within the 
testis are modulated by numerous paracrine and autocrine factors produced locally as 
means of cell-cell interactions (Huhtaniemi & Toppari, 1995; Jegou & Pinau，1995). 
1.5.2 Testicular vasculature 
In mammalian testes, the vascular system possesses several peculiar structural 
organizations which indicate that it has important control over the function of the 
testis (Bergh et al., 1993; Setchell，et al., 1994). These include a long unbranched 
testicular artery, the presence of a peritubular and an intertubular capillary network, 
the lining of the testicular vasculature by an unfenestrated endothelium and the failure 
of the capillaries to penetrate the seminiferous tubules. Due to the haemodynamic 
properties of a long unbranched blood vessel, the rate of blood flow to the testis is 
intrinsically limited by the testicular artery. An unfenestrated endothelium may 
hinder the passage of important macromolecules like the gonadotrophins, from blood 
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to their target cells in the extravascular tissues. In addition, the above problems 
could be compounded by the fact that the seminiferous tubules which make up the 
bulk of the testicular tissues and possess the actively dividing and differentiating germ 
cells are avascular. Since oxygen has to diffuse from the capillaries lying in the 
intertubular areas to the seminiferous tubules, the centre of these tubules has been 
shown to be at the brink of hypoxia (Setchell, 1978). This is especially true when 
the metabolism within the testis is increased (e.g. elevated testicular temperature) 
without being matched by a corresponding rise in blood flow. In the view of the 
limitations imposed by the anatomical arrangement of the testicular vasculature, a 
well-developed and maintained blood supply appears to extremely important to the 
normal activities within the testis and may provide the necessary local control of 
testicular function. In the vascular control within the testis, besides the acute effects 
from the alteration of the vascular permeability, and the regulation of blood flow by 
vasodilation or vasoconstriction, there is a medium- to long-term regulation by 
controlling the blood vessel formation or angiogenesis. 
1.5.3 Testicular angiogenesis 
It remains to be elucidated how the angiogenic process in the testis is initiated 
and controlled. However, quite a number of angiogenic factors have been found in 
mammalian testes, like acidic fibroblast growth factor (aFGF)，basic fibroblast growth 
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factor (bFGF)，platelet-drived growth factor (PDGF) and vascular endothelial growth 
factor (VEGF) (Ergun et al., 1997; Gnessi et al., 1995; Laslett et al” 1997; Murono et 
al, 1992; Norrby, 1997; Zheng et al., 1990). Among them, only VEGF has the 
signal peptide required for secretion and also it is mitogenic only to endothelial cells 
(Ferrara, 1996; Ferrara & Davis-Smyth，1997; Leung et al, 1989). So it makes 
VEGF a very attractive candidate for the study of how the angiogenic process is being 
regulated within the testis. 
1.6 Localization of VEGF and VEGF receptors in the testis 
The first report indicating the presence of VEGF in the testis was the work done 
in the mouse where VEGF transcripts were localized by in situ hybridization in the 
testicular interstitium, most likely associated with the Leydig cells (Shweiki et al” 
1993). Wan et al. (1996) were the first to report on the cloning of VEGF gene in the 
Leydig cells. Korpelainen et al (1998) demonstrated that VEGF and VEGF 
receptors were expressed in the testis and epididymis where overexpression of VEGF 
caused spermatogenic arrest, epithelial hyperplasia and infertility. Using 
immunohistochemical staining, Au et al (1997) and Collin & Bergh (1996) 
demonstrated that VEGF immunoreactivity was predominantly associated with the 
Leydig cells, though lower levels of expression were also found in the Sertoli cells 
and vascular smooth muscles. In line with the above findings, Ergun et al (1997) 
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used RT-PCR to demonstrate that in human testes VEGF mRNA was detected in 
Leydig cells and Sertoli cells. 
Using immunohistochemical staining, Au and his co-workers (Laslett et al, 1997) 
were the first to demonstrate the presence of flt-1 immunoreactivity in a population of 
testicular interstitial cells that took up the trypan blue dye, suggesting that they are 
testicular macrophages. In contrast, flk-1 immunoreactivity appeared to be 
associated exclusively with the Leydig cells. Both flt-1 and flk-1 have been partially 
cloned form rat testicular macrophages and Leydig cells respectively by Au et al., 
(1998). Flt-1 is likely to be involved in the interaction between Leydig cells and 
macrophages as indicated by the ability of VEGF to induce testicular macrophage 
migration in vitro (Au et al.’ 1998). In human testes, flt-1 mRNA was found by the 
technique of RT-PCR, to be expressed in testicular tissue, isolated fragments of 
testicular blood vessels and seminiferous tubules. In addition, flk-1 mRNA was also 
found in testicular tissue, isolated seminiferous tubules and testicular microvessels 
(Ergun et al.’ 1997). 
1.7 Aims of the present study 
Currently, five different mammalian VEGFs have been identified and they show 
unique expression patterns, receptor specificity and function. The parental vascular 
endothelial growth factor, VEGF-A, was discovered more than a decade ago. The 
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recently discovered, VEGF related peptides (VEGF-B, PIGF, VEGF-C and VEGF-D) 
share structural features typical of the VEGF family, but display different biological 
activities because of their different specificities for the three known VEGF receptors 
(VEGFR-1, VEGFR-2 and VEGFR-3). Reports in the literature have indicated that 
VEGF-A is expressed mainly in Leydig cells, Sertoli cells and vascular smooth 
muscle cells of blood vessels in the testis. Moreover, VEGFR-1 has been localized 
to vascular endothelium and testicular macrophages, while VEGFR-2 to vascular 
endothelium, Leydig cells and Sertoli cells. In the view of above findings, it is 
worthwhile continuing to explore the expression and cellular localization of the newly 
discovered VEGF family members in the testicular tissues, which is being the aim of 
the present study. Furthermore, how the expression of VEGF family members in the 
testis respond to hCG stimulation, and how this may be related to the presence or the 
activity of Leydig cells will also be examined. 
The present study is carried out using a combination of techniques, including 
RT-PCR, immunohistochemistry and Western immunoblotting. 
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2. Material and methods 
2,1 Animals 
Male Sprague-Dawley rats weighing between 350-450g were used. They were 
obtained from the Laboratory Animal Service Center of The Chinese University of 
Hong Kong. Animal studies were conducted in accordance with guidelines on the 
use of laboratory animals established by the Animal Ethics Committee of The Chinese 
University of Hong Kong. During the experiment, the rats were maintained in the 
animal holding room in the Department of Physiology, The Chinese University of 
Hong Kong. They were kept under a controlled environment of temperature 21 土 2 
�C，humidity below 75%, and a 12 hour light (06:00 - 18:00) / 12 hour dark (18:00 -
06:00) cycle. The animals had free access to tap water and rat chow. 
2.1.1 Depletion of Leydig cell 
To investigate whether Leydig cells are the source of VEGFs and PIGF, ethane-1， 
2-dimethane sulphonate (EDS, synthesized by The Department of Chemistry, The 
Chinese University of Hong Kong) treatment was used to selectively destroy the 
Leydig cells (Jackson & Jackson, 1984). EDS was dissolved in a 
dimethylsulphoxide (DMSO, Sigma, St. Louis, MO, USA) : water mixture (1:3 v/v) 
to a concentration of 75 mg/ml. Rats were injected intraperitoneally with a single 
dose of EDS (75 mg/kg bw) or the vehicle (DMSO : water). The rats were killed by 
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decapitation after three days and testes were removed and processed for RNA and 
protein extraction and immimohistochemical staining. 
2.1.2 Suppression of Leydig cell and stimulation by hCG 
Rats were anaesthetized by an intraperitoneal injection of 5% sodium 
pentobarbitone (Iml/kg) (Sigma, St. Louis, MO, USA), then received subcutaneous 
testosterone (Sigma, St. Louis, MO, USA)-filled silastic implants (Dow Coming, 
602-305; i.d. 1.98mm，o.d. 3.18mm) of either 3cm or 25cm in length for eight weeks 
to achieve Leydig cell suppression. The two lengths of testosterone implants were 
chosen based on the fact that the 3cm implants would produce normal levels of serum 
testosterone (Robaire et al., 1979) but could not provide adequate hormonal support to 
maintain normal spermatogenesis, while the 25cm implant would maintain near 
normal levels of spermatogenesis but in the presence of supraphysiological levels of 
circulating testosterone (Sun et al., 1989; McLachlan et al, 1994). Age-matched 
animals without bearing any subcutaneous silastic implants were used as the control. 
After 8 weeks of treatment, half the number of animals in the control and treatment 
groups received a single subcutaneous injection of 100 lU hCG (Pregnyl，Organon， 
Netherlands) in 0.2 ml phosphate-buffered saline (PBS) containing 0.01% bovine 
serum albumin (BSA) (Fraction V，protease-free; Sigma Chemicals Co., St. Louis， 
MO，USA) as the carrier protein while the other halves were injected with saline. 
24 
1 
They were killed two days post-hCG (or saline) by decapitation. Details of the 
experimental design are shown in Fig.2.1. 
2.1.3 Collection of tissue 
The testis was decapsulated and the testicular subcapsular artery was removed. 
The tissue was then divided roughly into equal portions which were then placed 
separately into sterile 0.6ml microcentrifuge tubes and snap frozen in liquid nitrogen. 
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Fig.2.1 Experimental design used in the study of the effect of Leydig cell suppression 
by 3 cm or 25 cm testosterone (T) - filled subcutaneous silastic implants on 
hCG-induced endothelial cell proliferation in adult rats testes. The animals were 
examined at 2 days post-hCG. 
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2,2 Preparation of primary cells from rat testes 
2.2.1 Sertoli cell preparation 
Sertoli cells were prepared from 20-day-old Sprague-Dawley rats following the 
methods described by Gorczynska & Handelsman (1993) and Gnessi et al (1995) 
with some modifications. The animals were killed by carbon dioxide asphyxiation. 
Testes were excised using sterile instruments and placed into 10 ml sterile Hanks' 
balanced salt solution containing 0.01% deoxyribonuclease (HBSS-DNase) (#DN25, 
Sigma, St. Louis, MO, USA). Subsequent procedures were carried out in a laminar 
flow hood using aseptic technique. After rinsing with HBSS-DNase, testes were 
decapsulated and contents were transferred to 5ml fresh HBSS-DNase. 
Seminiferous tubules were teased apart and chopped into small pieces for 15 minutes. 
The minced tissue was transferred into a sterile 50 ml Falcon tube and washed twice 
in HBSS-DNase, then made up to a total volume of 50ml. Every time after washing, 
the tissue was recovered by centrifugation at 250g for 3 minutes, and the supernatant 
was discarded. The tubule fragments were then digested in 10ml HBSS containing 
0.01% DNase, 0.1% trypsin (#18003, Sigma, St. Louis, MO, USA), 0.1% 
hyaluronidase (#H2551, Sigma, St. Louis, MO, USA) and 0.01% collagenase 
(#C9891，Sigma, St. Louis, MO, USA) in a shaking water bath (180 cycles per minute) 
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at 32 °C for 25 minutes. After digestion, the tissue was transferred to a sterile 50 
ml Falcon tube and again washed twice in HBSS-DNase in a final volume of 50 ml. 
The supernatant was discarded each time after centrifugation at 250g for 3 min at 
room temperature. At the end, the tissue pellet was resuspended in 12 ml Dulbecco's 
Modified Eagle Medium: Ham's F12 medium (DMEM/F-12, 1:1，v/v) (Gibco BRL, 
Grand Island, NY, USA, Cat. No. 12500-62) supplemented with 10% fetal bovine 
serum (Gibco BRL, Grand Island, NY, USA), 5 [ig/m\ human transferring (#T8158, 
Sigma, St. Louis, MO, USA), lOfig/ml bacitracin (#B0125, Sigma, St. Louis, MO, 
USA), 2.5 ng/ml epidermal growth factor (#E4127, Sigma, St. Louis, MO, USA) and 
lO^g/ml bovine insulin (#15500, Sigma, St. Louis, MO, USA). The cells were 
plated onto sterile culture plates (100 x 20 mm; Falcon, Becton Dickinson Labware， 
Franklin Lakes, NJ, USA) and placed in a water-jacketed carbon dioxide incubator 
(Napco Model 5100) maintained at 32°C under a humidified atmosphere of 5% 
carbon dioxide in air. The medium was changed the next day. On the second day 
of culture, the cultures were subjected to hypotonic treatment in 20mM TRIS (pH 7.4) 
for 2.5 minutes to lyses the residual germ cells. This was then followed by three 
washed with DMEM/F-12. On the fourth day of culture, the medium was aspirated 
and the cells that remained in the culture dish represented an enriched Sertoli cells 
preparation. They were ready for RNA and protein extraction. 
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It has been determined that such a Sertoli cell preparation has about 90% purity 
with the peritubular myoid cells as the major contaminating cell type (Ko et al, 2003). 
2.2.2 Germ cell preparation 
Germ cells were isolated from testes of 90-day-old mal Sprague-Dawley rats 
using the method described by Woodruff et al. (1992) with minor modifications. 
The testes were decapsulated and the tissue was transferred to a clean bottle. Twelve 
milliliters of DMEM/F-12 containing 30mg bovine serum albumin (#A3294, Sigma, 
St. Louis, MO, USA) and 3mg collagenase (Type I; Worthington Biochemical 
Corporation, Halls Mill Road, Freehold, New Jersey) were added and the bottle was 
tightly sealed. The digestion process by shaking in a water bath (110 cycles per 
minute) at 32°C for 20 minutes. At the end, tubules were dispersed in 50 ml 
DMEM/F-12 and shaken gently. Then tissue was allowed to settle for 5 minutes and 
the supernatant was discarded. The tubules were further washed three times with 
100 ml lOmM phosphate-buffer saline (PBS, pH 7.4, containing 9g/L sodium chloride 
and 1.56g/L sodium dihydrogen phosphate monohydrate) and shaken gently. Tissue 
was allowed to settle for 10 minutes and supernatant was discarded each time. The 
resulting tubules were thoroughly minced with scissors for 10 minutes and the minced 
tissue was transferred to a clean 50ml Falcon tube. PBS was then added to the tube 
to make up the final volume to 50 ml. After gentle shaking, the chucks of tissue 
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fragments were pelleted by centrifugation at 600g for 2 minutes. The supernatant 
collected after centrifugation was allowed to pass through a nylon pantyhose to 
remove aggregated cells and larger debris. The above steps were repeated two more 
times with the tissue pellets remaining at the bottom of the centrifuge tube. The 
resulting filtrate was added to a funnel packed with glass wool to remove the 
spermatozoa and then centrifuged at lOOg for 4 minutes. The supernatant was 
discarded and the pellet at the bottom of the tube was washed twice with 50 ml PBS. 
At the end, the pellet was resuspended in 10ml PBS and the cell suspension was 
filtered through 20|im nylon mesh. The final filtrate was centrifuged at 1500g for 5 
minutes. After pipetting off the supernatant, the cell pellet containing predominantly 
germ cells was ready for RNA and protein extraction. 
2.2.3 Interstitial cell and Leydig cell preparation 
The procedures used for preparing interstitial cells and Leydig cells were 
adopted from Murono et al. (1992) and Gnessi et al (1995). Both cell preparations 
were derived from testes of 90-day-old adult Sprague-Dawley rats. Testicular 
interstitial cells were obtained after collagenase digestion of the testes followed by 
crude cell separation by centrifugation. Leydig cells were obtained after subjecting 
the interstitial cells to a further purification step of Percoll density gradient 
centrifugation. 
3 0 
After the animals were killed by carbon dioxide asphyxiation, their testes were 
removed and decapsulated. The tissue was placed in a bottle containing 24ml or 
12ml 0.025% collagenase (Type I; Worthington Biochemical Corporation, Halls Mill 
Road, Freehold, New Jersey) solution in Medium 199 (Gibco BRL, Grand Island, NY, 
USA; Cat No. 21200-076) or DMEM/F-12 supplemented with 60mg BSA，10 
units/ml penicillin G sodium and lOug/ml streptomycin sulphate (Gibco BRL, Grand 
Island, NY, USA) for the preparation of Leydig cells and interstitial cells, respectively. 
Enzyme digestion was allowed to proceed in a shaking water bath (110 cycles per 
minute) at 32°C for 20 minutes. At the end, 80ml DMEM/F-12 supplemented with 
antibiotics and 0.2% BSA (for interstitial cell preparation) or 50 ml Medium 199 
supplemented with antibiotics (for Leydig cell preparation) was added to the bottle 
and testicular tissue was allowed to settle for 5 minutes. The supernatant was 
pipetted off to 50ml Falcon tubes. For preparing Leydig cells, 25 ml medium 199 
was again added to the tubes. Similarly, for preparing interstitial cells, DMEM/F-12 
with 0.2% BSA was added to the tubes to make up the final volume to 50 ml. The 
cells were collected in the supernatant after gently swirling and until sedimentation. 
After the above steps, the supernatant was pooled and centrifuged at 350g for 10 
minutes. For preparing interstitial cells, 10ml PBS was added to wash the cell pellet 
twice. The tubes were centrifuged at 350g for 5 minutes and the supernatant was 
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then discarded each time. The cell pellet was finally ready for RNA and protein 
extraction. 
For preparing Leydig cells, the cell pellet was recovered and resuspended in a 
small volume of Medium 199: BSA (50ml of Medium 199 supplemented with 10 
units/ml penicillin G sodium, lO^ig/ml streptomycin sulphate and 50mg BSA). The 
cells were pooled and layered on top of a discontinuous Percoll (Amersham 
Pharmacia Biotechnology, Buckinghamshire, UK) gradient with density of 1.030， 
1.040，1.055, 1.065，1.070 and 1.096 g/L set up in 50ml Falcon centrifuge tube. The 
gradient was centrifuged at 900g for 20 minutes. Cells localizing at Percoll gradient 
density of 1.070g/L were saved as the Leydig cell enriched fraction. Medium 199: 
BSA (50ml of medium 199 supplemented with 10 units/ml penicillin G sodium and 
10 |Lig/ml streptomycin sulphate and 50mg BSA) was added to wash the Leydig cells 
three times, with centrifugation at 350g for 10 minutes in between each washing step. 
The resulting Percoll purified Leydig cells were then ready for RNA and protein 
extraction. 
2.3 Cell cultures 
2.3.1 Reagents and cell lines 
Testicular cell lines (TM3, TM4，MLTC-1，R2C and LC540) were obtained from 
the American Type Culture Collection (Rockville，MD) and maintained under 
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recommended conditions. 1:1 Dulbecco's modified Eagle Medium (DMEM): Ham's 
F12 Medium (Cat. No. 12500-062), RPMI1640 medium buffered with 25mM HEPES 
(Cat. No. 23400-021), Ham's FIO medium (Cat. No. 81200-040)，Minimum Essential 
Medium (Eagle) in Earle's BSS (Cat. No. 41500-067)，fetal bovine serum, horse 
serum, penicillin G (sodium salt) and streptomycin sulphate were purchased from 
Gibco BRL, Grand Island, New York, USA. Sodium bicarbonate and D-glucose 
were obtained from BDH Chemicals Ltd, Poole, England. HEPES (without sodium 
salt was purchased from Boehringer Mannheim, Germany. Nonpyrogenic tissue 
culture plates (100 x 20 mm; Polystyrene) were from Becton Dickinson Labware, 
Becton Dickinson and Company, Franklin Lakes, NJ, USA. 
2.3.2 Mouse Leydig cell line, TM3 and Sertoli cell line, TM4 
Based on information provided by the supplier (ATCC)，both TM3 and TM4 
cells are clonal cell lines isolated respectively from primary cultures of Leydig cell 
enriched preparations and Sertoli cell enriched preparations from normal testes of 11 
to 13-day-old BALB/c nu/+ mice. They were maintained in a 1:1 mixture of 
Dulbecco's Modified Eagle Medium (DMEM)/Ham's F12 medium supplemented 
with 4.5g/L glucose, 1.2g/L sodium bicarbonate, 15 mM HEPES, 10 units/ml 
penicillin G (sodium salt) and 10|ig/ml streptomycin sulphate, 5% horse serum and 
2.5% fetal bovine serum. The cultures were kept at 37°C in a water-jacketed CO2 
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incubator (Nuaire, US Autoflow, Techcomp) and media were changed every 3 to 4 
days. The cells were passaged at a dilution ratio of 1:10 after a period of 4 to 5 days 
and harvested at 80-90 % confluence. 
2.3.3 Mouse tumor Leydig cell line, MLTC-1 
According to the information provided by the supplier, MLTC-1 is a tumour cell 
line of mouse Leydig cells derived from the M5480P transplantable Leydig cell 
tumour carried in C57BL/6 mice. The cells were cultured in RPMI 1640 medium 
containing 25inM HEPES, 10% fetal bovine serum, 10 units/ml penicillin G sodium 
and 10|Lig/ml streptomycin sulphate at 37°C under a humidified atmosphere of 5% 
CO2. The medium was replaced every 3 to 4 days and the cells were passaged at a 
split ratio of 1:3 at 5 to 6 days intervals. 
2.3.4 Rat tumor Leydig cell line, R2C 
A tumour cell line of rat Leydig cells, R2C, is derived from testes of 
two-month-old male rat. The cells were cultured in Ham's FIO medium 
supplemented with 15% horse serum, 2.5% fetal bovine serum, 10 units/ml penicillin 
G sodium and I0\xg/m\ streptomycin sulphate supplements of 1.5g/L sodium 
bicarbonate and 2 mM L-glutamine. The cells were kept at 37°C in a humidified 
50/0 CO2 atmosphere and the cells were fed every 3 days. They were passaged upon 
confluence at a split ratio of 1:3 at 3 to 5 days intervals. 
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2.3.5 Rat tumor Leydig cell line, LC540 
LC540 Leydig cells are derived from Fischer male adult rat. They were grown 
in Minimum Essential Medium (Eagle) in Earle's BSS supplemented with 
non-essential amino acids, ImM sodium pyruvate and 10% fetal bovine serum. The 
medium also had 10 units/ml penicillin G sodium and 10|ag/ml streptomycin sulphate 
added as antibiotics. The cells were kept in a humidified 5% CO2 atmosphere at 37 
°C, and the medium was changed every 3 to 4 days. The cells were passaged at a 
split ratio of 1:3 after a period of 3 to 5 days. 
2,4 Reverse-transcription polymerase chain reaction (RT-PCR) and 
semi-quantitative RT-PCR 
2.4.1 Extraction of total RNA 
Total RNA was isolated from testicular cell lines and testicular tissues using 
TRIZOL reagent (1ml / lOOmg) (Gibco BRL, Grand Island, NY, USA) following the 
procedure suggested by the manufacturer. The tissue was homogenized by hand on 
ice in a 3-ml glass homogenizer with a clearance of 0.004-0.006 inch (Kontes 
Scientific Glasswarer/ Instruments, Vineland, NJ，USA) with TRIZOL reagent. The 
tissue homogenate was centrifuged at 12，000g for 20 minutes at 4°C to collect the 
supernatant. 
For testicular cell lines and primary cells, one millilitre of TRIZOL reagent was 
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added to the cell pellet and the cell suspension was passed several times through a 1 
ml gauge 25 syringe (Terumo, Tokyo, Japan) to disrupt the cells. 
Phase separation was carried out for both tissue homogenate and cell lysate. The 
sample was incubated at room temperature for 15 minutes to allow thorough 
dissociation of nucleoprotein complexes. For every ml of TRIZOL reagent initially 
used for homogenization，200 of chloroform was added. The sample tubes were 
then capped securely and hand-shaken vigorously for 15 seconds. After 3 minutes of 
incubation at room temperature, they were subjected to centrifugation at ll，000g for 
15 minutes at 4 °C . The sample mixture was separated into a lower red， 
phenol-chloroform phase and a colorless upper aqueous phase after centrifugation. 
The upper aqueous phase containing the RNA was transferred into a clean 1.5 ml 
microcentrifuge tube. RNA precipitation was achieved following the addition of 500 
|Lil isopropyl alcohol to every milliliter of TRIZOL reagent initially used for 
homogenization, and allowing the sample to incubate at room temperature for 10 
minutes. The RNA was harvested after centrifugation at 11，OOOg for 10 minutes at 4 
�C，washed once with 1ml 70% ethanol and then pelleted again by centrifugation at 
7，500 for 5 minutes at 4°C. After carefully discarding the supernatant, the residual 
ethanol associated with the RNA pellet was removed by vacuum-drying for 5 to 10 
minutes in the SpeedVac (DNA SpeedVac 110，Savant Instruments Inc., NY, USA). 
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The RNA was re-dissolved in an appropriate volume of diethylpyrocarbonate 
(DEPC)-treated water and stored at -70°C until use. All the above procedures were 
carried out under RNase-free condition to prevent RNA degradation. 
2.4.2 Quantitation of total RNA 
RNA concentrations and purity were determined based on the absorbance at 260 
nm (A260) and 280 nm (A280) by spectrophotometry (Ultrospec Spectrophotometer, 
Amersham Pharmacia Biotechnology, Buckinghamshire, UK) after the samples were 
diluted a hundredth time with DEPC-treated water. An absorbance of 1 unit at 260 
nm corresponds to 40 ^g of RNA per ml. The following formulae were then used to 
calculate RNA concentration, total yield and purity of each sample: 
> RNA concentration (|ag/|il) = (40 x A26O x dilution factor) /1000 
> Total yield (|ig) = RNA concentration x total volume of RNA sample (|il) 
> RNA purity = A26O 丨 A280 
The ratio of absorbance readings taken at 260nm and 280nm (A26O 丨 A280) 
provides an estimate of the purity of the RNA sample. Only when this ratio lies 
between 1.5 and 1.9 would the RNA preparation be considered acceptably pure. 
2.4.3 RT-PCR 
Five microgram of total RNA per sample was used for cDNA synthesis 
employing Superscript ™RNase H' Reverse Transcriptase (200}xg/ reaction) (Gibco 
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BRL, Grand Island, NY, USA) and oligo-deoxythymidine primers (0.5 |Lig/ reaction) 
(Gibco BRL, Grand Island, NY, USA). Reverse transcription was performed by 
heating 12 jiil reaction mixture of 5 )ig RNA sample and 0.5 
oligo-deoxythymidine primers to 70°C for 10 minutes. Afterwards, the mixture was 
immediately chilled on ice for 2 minutes. Following the addition of 7 |li1 mixture of 
5 times first strand buffer, 0.1 M dithiothreitol (DTT) and 10 mM each of the 
deoxynucleotidetriphosphates (dNTPs) (Gibco BRL, Grand Island, NY, USA), the 
reaction mixture was again heated to 42°C for 2 minutes. 1 of Superscript tm 
RNase H" Reverse Transcriptase (200 units) was added last to the reaction mixture to 
reach a final volume of 20 The reaction was allowed to proceed for 50 minutes 
at 42°C，and then followed by a final extension of 15 minutes at 72°C. The cDNA 
thus synthesized was stored at -20 °C until use. p-actin was chosen as a 
house-keeping gene (or as an internal control) to approximate the same amounts of 
cDNA used for different samples in the same PGR. The amplification of P-actin 
cDNA also served as an indicator of successful RNA isolation and reverse 
transcription. 
PGR conditions for specific gene products were optimized for primer annealing 
temperature, concentration of magnesium chloride, PGR cycle number and initial 
amounts of cDNA template used for each primer set. RT-PCR experiments were 
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performed using pairs of specific primers for P-actin, VEGF-A, PIGF, VEGF-B， 
VEGF-C and VEGF-D. Primers used in the present study were purchased from 
Gibco BRL, Grand Island, NY, USA. Table 2.1 shows the list of primer sequences 
designed based on published cDNA sequences. Table 2.2 summarizes the optimal 
primer annealing temperature, concentration of magnesium chloride, PGR cycle 
number and additives used for the amplification of each PGR product. The number 
of cycles chosen for semi-quantitative RT-PCR was determined after a series of 
experiments involving template and cycle titration to establish that it was located at 
the exponential phase of the polymerase reaction (Fig.2.1 to 2.4). 
Variable amounts of template, lOmM magnesium chloride, 2|il of lOX PGR 
buffer, l|Lil of 10 mmoles each dATP, dGTP, dCTP and dTTP, 1 i^l each of the sense 
and anti-sense primers (20 pmoles), and 0.5|al of 5 units per t^l Tag DNA polymerase 
(Gibco BRL, Grand Island, NY, USA) were used for each PGR. It was carried out in 
thin wall 0.6ml PGR tubes (Robbins Scientific Corporation, Sunnyvale, CA). Master 
mixes were applied when possible to minimize tube-to-tube variations. The PGR 
amplification was performed in 20 i^l volumes using the PTC-200 thermal cycler (M. 
J. Research, Inc., San Francisco, USA) with the program set at 94°C for 3 minutes 
(initial denaturation of cDNA), 94°C for 1 minute (optimal temperature cycles of 
denaturation), 58 °C for 45 seconds (primer annealing), 72 °C for 1.5 minutes 
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(enzymatic reaction of extension), 72°C for 10 minutes (final extension). 
The PGR products were kept at 4�C or stored at -20�C. After PGR, 2 |il of 
each reaction product was analyzed by electrophoresis on 1.2 - 2.0 % agarose (Gibco 
BRL，Grand Island, NY, USA) gel containing 0.5 mg/ml ethidium bromide (Gibco 
BRL, Grand Island, NY, USA) in TAB buffer (40mM TRIS, 20mM sodium acetate, 
ImM EDTA, pH 7.2). The relative intensity of the product bands were recorded and 
analyzed using a Fluorchem™ 8000 gel documentation system (Alpha Innotech 
Corporation). 
For the semi-quantitation of the obtained gene signals in the treatment studies, 
the densitometric quantification of the gene signals were ratioed against p—actin， 
which was taken as an internal control, and then normalized against the control animal 
as 100 o/o. 
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Table 2.1 Primers used for the PCR amplification of P-actin, VEGFs and 
VEGFRs. 
pj^jmers GenBank Primer Sequences Expected Product 
(S: sense; Accession (5，to 3') Size (bp) 
AS : antisense) Number 
p . a c t i n [ S AF122902 5’-TCA CCG AGG CCC CTC TGA 643 
ACC CTA-3，(nt. 314-337) 
5，-GGC AGT AAT CTC CTT CTG 
CATCCT-3’（nt. 934-957) 
VEGF-A "S NM一031836 5’-ATG AAC TTT CTG CTC TCT 392 
TGG GTG C-3’ (nt. 1-25) 
5，-GGT CTG CAT TCA CAT CTG 
CT-3，(nt. 373-392) 
V E G F - A S NM-031836 5’-ATG AAC TTT CTG CTC TCT 645-VEGF-Ai88, 
(for TGG GTG C-3’ (nt. 1-25) 573-VEGF-Ai64, 
spliced 5'-TCA CCG CCT TGG CTT GTC 513-VEGF-Ai44, 
variants) ACA-3’ (nt. 625-645) 441-VEGF-Ai2o 
S NM_053595 5，-AGG TCC TAG CTG GGT TGG 383 
CTGT-3' (nt. 74-95) 
" X s 5 ' - C C T CCT TTC TGC CTT TGT 
CGT CTC C-3’ (nt. 432-456) 
Y E G F - B S AF022952,5'-GTG ACT GTG CAG CGC TGT 324-VEGFi67, 
AF032925 GGT-3’（nt. 125-145 or 68-88) 425-VEGF-Bi86 
" X s 5 ' - G G T GTC TGG GTT GAG CTC 
TAA GC-3, (nt. 426-448) 
V E G F - C S AY032729 5，-GGA GAA AGA CTC AAT GCA 253 
TGC CAC G-3’ (nt. 452-476) 
" X s 5 ' - C G G CAG GAA GTG TGA TTG 
GCA AAA C-3 ’ (nt. 680-704) 
V E G F - D S AY0327285'-CAC TCT GAG GAC TGG AAG 233 
CTG T-3’(nt. 231-252) 
5'-GGG GGC TTG AAG AAT GTG 
TTG G-3 ’ (nt. 442-463) 
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Table 2.2 Optimal primer annealing temperature, MgCh concentration, PCR 
cycle numbers and additives used for each reaction. 
；；^ A n n e a l i n g M g C h PCR Cycle Additives 
Temperature Concentration Numbers 
^ (rm 
P-actin - 70 1.5 _ 18 丨-
VEGF-A 62 1.5 ^ L 
V E G F - A ^ ^ 2.0 30 / 
spliced variants) 
PIGF 70 — 1.5 ^ / 
VEGF-B — 70 — 1.5 ^ ‘ 
VEGF-C — 70 1.5 ^ i 
VEGF-D 67 1.0 28 2% formamide 
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(A) Template titration of VEGF-A (spliced variants) 
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Fig.2.1 Template and cycle titration of PCR amplification for VEGF-A mRNA in 
the rat testis. VEGF-A gene expression in rat testis as detected by RT-PCR. 
(A)-(B) Template titration of VEGF-A mRNA, (C)-(D) Cycle titration of VEGF-A 
mRNA. 
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(A) Template titration of VEGF-B 
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Fig.2.2 Template and cycle titration of PCR amplification for VEGF-B mRNA in 
the rat testis. VEGF-B gene expression in rat testis as detected by RT-PCR. 
(A)-(B) Template titration of VEGF-B mRNA, (C)-(D) Cycle titration of VEGF-B 
mRNA. 
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Fig.2.3 Template and cycle titration of PCR amplification for VEGF-C mRNA in 
the rat testis. VEGF-C gene expression in rat testis as detected by RT-PCR. 
(A)-(B) Template titration of VEGF-C mRNA, (C)-(D) Cycle titration of VEGF-C 
mRNA. 
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(A) Template titration of VEGF-B 
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Fig.2.4 Template and cycle titration of PCR amplification for VEGF-D mRNA in 
the rat testis. VEGF-D gene expression in rat testis as detected by RT-PCR. 
(A)-(B) Template titration of VEGF-D mRNA, (C)-(D) Cycle titration of VEGF-D 
mRNA. 
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2.4.4 Purification and authentication of PGR products 
Gene-Clean Kit II (Bio 101) was used to purify the amplification products. 
Specific bands identified after electrophoretic separation of PGR products were 
excised with a razor blade under transillumination using long-wave ultraviolet light. 
In this step, minimal amount of agarose gel was isolated and it must be carried out in 
the shortest time possible to avoid nicking of DNA. The net weight of the agarose gel 
slice was determined and used for calculating the volume of sodium iodide (6M) 
needed to solubilize the gel (3:1; Nal : gel) in a water bath at 55�C with occasional 
mixing. 
The GLASSMILK suspension was provided in the Gene-Clean Kit II, and it was 
thoroughly mixed by votexing before use. 5 [ii of the GLASSMILK was added to 
each sample and incubated for 5 minutes at room temperature with occasional mixing. 
This GLASSMILK suspension was an aqueous suspension of proprietary silica matrix 
which only binds to single and double stranded DNA. Afterwards, the 
GLASSMILK with the bound DNA was separated by centrifugation at 11,600 g for 5 
seconds. After discarding the supernatant, GLASSMILK was washed three times 
with 500 “New Wash Solution" (a concentrated solution of sodium chloride, TRIS 
and EDTA in water and ethanol). After the final wash and centrifugation, as much 
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"New Wash Solution" was removed and the pellet was resuspended in 10 
DEPC-treated water and incubated in a water bath at 55°C for 2 to 3 minutes to 
recover the DNA from the GLASSMILK. The DNA present in the supernatant was 
separated from the GLASSMILK after centrifugation at 11,600 g for 30 seconds. 
The quantity of DNA recovered was estimated by gel electrophoresis and compared 
against a low DNA mass ladder (Gibco BRL, Grand Island, NY, USA). 
After purification, the authenticity of the PCR product was verified by forward 
or reverse sequencing using a dRhodamine Terminator Cycle Sequencing Kit (Perkin 
Elmer, Applied Biosystems, California, USA) and an automated sequencer (Advanced 
ABI 310 Genetic Analyzer, Perkin Elmer, Tokyo, Japan), following the procedure 
recommended by the supplier. The sequencing data were submitted to the BLAST 
Search (NCBI, National Center for Biotechnology Information; website: 
http://www.ncbi.nlm.nih.gov.BLAST) to confirm the authenticity of PCR products. 
2.5 Immunohistochemical staining 
2,5,1 Perfusion and processing of testes for histological sections 
The testis was excised from the animal after it was freed from the epididymis. 
Using a scalpel blade (size #24, Swann-Morton, Sheffield, England), a small cut was 
made in the testicular subcapsular artery along its course down the epididymal margin 
of the testis and close to where it enters the tunica albuginea at the cranial pole of the 
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testis. A cannula constructed from polythene tubing (0.5mm i.d.，1.0mm o.d.， 
800/110/160，Portex, UK) and heat-drawn to a tip diameter of about 100|Lim diameter 
was inserted into the subcapsular artery along the direction of normal blood flow. 
Pre-warmed (25-30°C) heparinized saline (50 U/ml of a sodium salt of heparin from 
porcine intestinal mucosa in normal saline; Sigma, USA) was infused into the testis 
by hand using a 5ml syringe fitted with a gauge 23 needle (Tenimo, Tokyo, Japan). 
Care was taken to prevent the entry of air bubbles. The volume of infusate (1-3 ml) 
was adjusted until there was a complete removal of blood. Following the saline 
infusion, 1.5-2.0 ml of Bouin fixative was infused until it distributed uniformly 
throughout the testis. 
After the initial fixation by perfusion, the perfused testis was immersion-fixed in 
Bouin solution for 24 hours at room temperature, followed by another 24 hours at 4°C. 
After the first 24 hours, the testis was cut using a microtome blade (S35，Feather, 
Japan) into 2mm thick slices at right angle to its cranial-caudal axis. 
After fixation, the testes were transferred to 70% ethanol saturated with lithium 
carbonate and washed 4 to 5 times to neutralize and remove picric acid left from the 
Bouin fixative. A slice of tissue (about 2 mm thick) was taken from the central part 
of each testis and put through a tissue processor for dehydration in ethanol and 
clearing in xylene. The timings of the above steps were as follow: 80% ethanol (2 
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hours), 95% ethanol (2 hours), 3 changes of 100% ethanol (1 hour each) and 2 
changes of xylene (1 hour each). Then tissue sections were ready for embedding in 
paraplast (Paraplast X-TRA, melting point 50-54°C, Oxford Labware, St. Louis, MO, 
USA) after 2 changes of Paraplast X-TRA (1 1/2 hours each). Five-micron sections 
were cut using microtome (Model 1130，Biocut, Reichert-Jung, Germany) and 
mounted on glass slides coated with 1% 3-aminopropyltriethoxysilane (APES) 
(Sigma, St. Louis, MO, USA) in ethanol. 
2.5.2 Immunohistochemical staining of tissue sections 
Reagents used for immunohistochemical staining are from Zymed Laboratories 
Inc. (South San Francisco, USA) and they are based on the 
streptavidin-biotin-peroxidase method. The procedures were carried out according 
to the manufacturer's instructions with some modifications. Five microns testis 
sections were dewaxed in two changes of (R)-(+)-limonen (Merck, Germany) (4 
minutes each), rehydrated through a down-series of ethanol (2 changes of 2 minutes 
each in absolute ethanol (Merck, Germany), one wash for 2 minutes in 95% ethanol, 
one wash for 5 minutes in 70% ethanol saturated with lithium carbonate), then placed 
for 5 minutes in distilled water, 5 minutes in 300mM glycine (Bio-Rad, CA, USA) 
and finally equilibrated in lOmM phosphate-buffer saline (PBS, pH 7.4). The tissue 
endogenous peroxidase activity was quenched by treatment with 3% H2O2 (Merck, 
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Germany) in PBS for 10 minutes. 
Before reacting with the antibodies, the testis sections were further subjected to 
an antigen retrieval procedure to unmask the antigenic sites for antibody binding. 
The slides were heated in O.OIM citrate buffer (pH 4.1) for 20 minutes at 95°C and 
then left to cool in the same buffer for 20 minutes at room temperature. 
The VEGF antibodies, including VEGF-A (A20)，VEGF-B (P19)，VEGF-C 
(HI90) and VEGF-D (HI44) were commercially available from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA. Owing to no suitable commercially available 
PIGF antibody could be used for the immunohistochemical staining, this part of study 
was omitted. They were used at 1:200 for VEGF-A and 1:50 for the others in PBS 
containing 20% fetal calf serum (FCS) (Gibco BRL, Grand Island, NY, USA). The 
incubation was carried out for one hour at room temperature, after which the antibody 
was rinsed off and replaced by the biotinylated secondary antibody (goat anti-rabbit 
IgG for VEGF-A, C, D or swine anti-goat IgG for VEGF-B) used at 1:75 dilution for 
10 minutes at room temperature. In between steps, the sections were rinsed three 
times at 2 minutes intervals with PBS. Following reaction with the second antibody, 
peroxidase-conjugated streptavidin (diluted 1:400 in PBS) was added and left for 10 
minutes at room temperature. Finally, specific staining of the antigen was visualized 
by the addition of the chromogen, the AEC reagent, which gave a red color after 
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15-30 minutes incubation at room temperature. After immunostaining, the sections 
were counterstained with haematoxylin and mounted without dehydration in an 
aqueous mountant (polyvinyl pyrrolidone). 
The positive immuno staining was examined under light microscope and areas of 
interest were recorded using a Leica microscope fitted with a high resolution CCD 
camera. The images were captured on computer files using the LEICA QWin 
Standard (version. 2.0 for Windows, Leica Imaging System). 
2,6 Western immunoblotting 
2.6.1 Extraction and quantitation of total protein 
Tissues were homogenized by hand on ice in 3 ml glass homogenizers with 
clearance of 0.004-0.006 inch (Kontes Scientific Glasswarer/ Instruments, Vineland, 
NJ, USA) and cell pellets were passed several times through a 1 ml gauge 25 syringe 
(Terumo, Tokyo, Japan) to disrupt the cells in 10 mM Tris-HCl buffer (pH 7.4) 
supplemented with protease inhibitors (l|xg/ml leupetin, 5 jag/ml aprotonin, 100|ig/ml 
phenylmethylsulfonyl fluoride (PMSF), ImM sodium orthovanadate, ImM EGTA， 
ImM EDTA, and phosphatase inhibitors containing sodium fluoride, 
P-glycerolphosphate and HEPES at pH 7.3). The supernatant was collected after 
centrifugation at 15,OOOg for 20 minutes at 4°C. All procedures were done on ice or 
at 4°C to minimize protein degradation. The protein concentration of tissue 
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homogenates was determined using the Bio-Rad DC Protein Assay (Bio-Rad, CA, 
USA) according to the manufacturer's instructions. After determination of the 
protein concentration, the samples were aliquoted and stored at -80°C until use. 
Each tissue lysate was mixed with an equal volume of double-strength 
electrophoresis sample buffer (125 mM Tris，pH 6.8，4% sodium dodecyl-sulphate 
(SDS)，20% glycerol, 10% P-mercaptoethanol) and boiled for 5 minutes at 100°C to 
denature the protein. For the immunoblotting of VEGFs and its receptors, 40 ^g and 
80 i^ g of total protein were used respectively for each sample. 
2.6.2 SDS-PAGE 
150/0 acrylamide gel (Bio-Rad, CA, USA) was used for the separation of VEGFs 
and PIGF. They were prepared by mixing deionized water (1 volume for 15%, 2 
volumes for 7.5%)，Tris-base buffer (pH 8.8, Bio-Rad, CA, USA) (1 volume for 15% 
and 7.5%) and acrylamide: bisacrylamide (Bio-Rad, CA, USA) (37.5:1 w/w) (30% 
w/v solution in H2O) (2 volumes for 15%, 1 volume for 7%). Tetramethylethylene 
diamide (TEMED, Bio-Rad, CA, USA) and freshly prepared ammonium persulphate 
(Bio-Rad, CA, USA) were then added to a final concentration of 0.1%. After 
thorough mixing, it was transferred to fill the space between the two glass plates on 
the casting stand. Isopropanol was overlay on top of the gel to give it a level surface， 
and the gel was allowed to polymerize for 40 minutes. After the separating gel had 
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set, isopropanol was discarded and the top of the gel was rinsed five times with 
deionized water. The area above the separating gel was dried by soaking with filter 
paper before the stacking gel was poured. 
4% acrylamide stacking gel was prepared by thoroughly mixing water (4.5 
volumes), upper Tris-base buffer (pH 6.8) (2 volumes), acrylamide: bisacrylamide 
(37.5:1 w/w) (30% w/v solution in H2O) (1 volume), tetramethylethylene diamide 
(TEMED, to a final concentration of 2%) and freshly prepared ammonium 
persulphate (to a final concentration of 0.1%). Then it was overlay on top of the 
separating gel, and the comb used for casting the sample wells was inserted. The 
polymerization was allowed to proceed for 40 minutes. 
After the gel had set, the comb was carefully withdrawn and the wells were 
rinsed 3 times with Tris-glycine electrophoresis running buffer. The wells were kept 
moist by filling them with running buffer, and the sandwich unit of gel and glass 
plates was clamped to the electrophoresis assembly. 
Denatured protein samples (40 or 80 jig per lane), prestained molecular size 
markers (Low range molecular size prestained marker showing band sizes of 21.4 to 
111 kDa, Bio-Rad, CA，USA) and a biotinylated molecular size marker (showing 
band sizes of 14.3 - 97.4kDa，Sigma, St. Louis, MO, USA) were loaded respectively 
into each sample well of the polyacrylamide gel. After placing the electrophoresis 
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assembly unit into the lower buffer chamber, both the upper and lower chambers were 
filled with running buffer. Air bubbles adhering to the lower edge of the gel were 
removed using a U-shaped pasteur pipette. After checking for leakage, the 
electrophoresis unit was connected to a power supply. Electrophoresis was 
performed under a constant voltage of 60 - 120 V until the proteins had achieved a 
desirable separation as indicated by the migration of the prestained marker. 
2.6.3 Immunoblotting 
The polyacrylamide gel was removed from the electrophoresis assembly and 
equilibrated in transfer buffer (Tris-glycine, 0.0375% SDS，20% methanol) for 20 
minutes. Polyvinylidene difluoride membrane (PVDF, Immobilon-PSQ, Millipore 
Corporation, Bedford, USA) was soaked briefly in methanol for 15 seconds and then 
in transfer buffer for another 20 minutes. 
For VEGFs and PIGF, electroblotting was carried out either using a Trans-Blot 
Semi-Dry Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA, USA) 
according to the manufacturer's instructions for 35 minutes under a constant voltage 
of 18V，or wet transfer (which was performed at about 4�C by placing an ice block 
inside the transfer tank) according to the manufacturer's instructions in a Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA, USA) for 1 hour 
at a constant voltage of lOOV. 
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After electroblotting, the membrane was briefly washed three times with 
deionized water before being blocked for one hour at room temperature with 5% skim 
milk (Carnation) for VEGFs or 2% bovine serum albumin (BSA, Sigma, St. Louis， 
MO, USA) for PIGF. The blocking solutions were made up in PBS-Tween 
(polyoxyethylene sorbitan monolaurate, Sigma, St. Louis, MO, USA) (PBST). 
Overnight incubation with rabbit polyclonal primary antibodies [1:500 dilution for 
VEGF-A (A-20), VEGF-B (H70)，VEGF-C (H190) and VEGF-D (H144) in 5% skim 
milk, and PIGF (R18) in 2% BSA at room temperature] were carried out on a roller 
mixer. On the next day, membrane was then washed three times with PBST and 
incubated with secondary peroxidase-conjugated goat-anti-rabbit antibody or 
secondary peroxidase-conjugated rabbit-anti-goat antibody (DAKO A/S, Denmark) 
(1:3000 or 1:5000 dilution in blocking reagent) for 1 hour in room temperature. 
After further washing, specific protein bands on the membrane were visualized after 
incubation in ECL reagent (Amersham Pharmacia Biotechnology, Buckinghamshire, 
UK) for 1 minute followed by exposure to X-ray film (FujiFilm, Japan). The position 
of the biotinylated molecular size markers were subsequently determined after 
incubating the membrane with streptavidin-peroxidase (1:5000 dilution) for 30 
minutes at room temperature followed by chemiluminescence detection using ECL 
reagent and X-ray film. In the control experiment, incubation with the primary 
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antibody was omitted and the blot was only exposed to the diluent of the secondary 
antibodies. This served to determine if any of the signals that finally appeared 
would be non-specific. 
2.7 Statistical analyses 
Data were expressed as mean 土 standard error, with the number of animals or 
replicates given by the value of n. Statistical analyses were performed using a 
commercially available software package (SigmaStat for Windows, ver. 1.0，Jandel 
Scientific Software, San Rafael, CA, USA). Non-parametric tests were used for data 
that were expressed as percentages of the control. Kruskal-Wallis one-way ANOVA 
on Ranks was used to determine if significant differences existed among the various 
experimental groups. This was then followed by the use of Dunnett's test for 
comparing treatment groups against the control. For comparison between two 
groups, Mann-Whitney rank sum test was used. P value of less than 0.05 was taken 
as statistically significant. 
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3. Results 
3.1 Expression and localization of VEGFs in the rat testis 
3.1.1 VEGF-A 
Using immunohistochemical staining, VEGF-A immunoreactivity was localized 
mainly in the intertubular area within the cytoplasm of the interstitial cells which were 
mainly composed of Leydig cells. Moreover, immunoreactivity was found in Sertoli 
cells and vascular smooth muscle cells, though their immunoreactivity appeared weaker 
(Fig.3.1Aand B). 
In this and subsequent immunostaining studies, the specificity of the 
immunohistochemical staining was tested by omitting of the primary antibody. They all 
resulted in the complete disappearance of the positive immunoreactivity with no 
background staining (Fig 3.1 I to L). 
In the RT-PCR analysis, VEGF-A transcripts were demonstrated in the normal 
rat testis, cultured rat primary cells and cell lines by specific primers, though they 
showed different expression patterns and intensities (Fig.3.2). PCR products separated 
on ethidium bromide-stained agarose gel showed four mRNA spliced variants of with 
expected sizes of 645 bp, 573 bp, 513 bp and 441 bp encoding the four VEGF-A 
isoforms ofVEGF-Aigg, VEGF-A164�VEGF-A144 and VEGF-A120 respectively. Among 
the four isoforms, VEGF-Ai88, VEGF-Ai64 and VEGF-Ai20 appeared to be the major 
forms and were found in most cell types, including Leydig cell and Sertoli cell. The less 
abundant VEGF-A 144 transcript was clearly demonstrated in total RNA extracted from 
cells but not testicular tissue. The five testicular cell lines cover two cell types: Leydig 
cells (LC540, R2C，MLTC-1 and TM3) and Sertoli cells (TM4). According to this 
categorization, VEGF-A transcripts found in all these cell lines was an evidence 
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confirming that VEGF-A transcripts were expressed in Leydig cells and Sertoli cells 
(Fig.3.2B). 
By adjusting the amounts of template used in PCR based on the signal intensity 
from the amplification of the internal control, p-actin, and the PCR was conducted 
during the exponential phase of the reaction, a semi-quantitative estimate of the relative 
abundance of VEGF-A mRNA in different cell types was achieved. Based on this semi-
quantitative comparison, VEGF-A transcript expression in the Leydig cell appeared to 
exhibit the strongest signal among the primary cells (Fig.3.2A), indicating that it 
probably was the major source of VEGF-A transcripts in the testis. 
The authenticity of the products was confirmed by DNA sequencing using an 
automated DNA sequencing and analysis system (data not included). Primers were 
designed in such a way that they span over a region of intron of the targeted gene such 
that any genomic DNA contamination in the RNA and hence cDNA preparation, would 
yield PCR products of larger sizes. Furthermore, this was regularly tested by showing 
the absence of signals from RT-PCR performed without the addition of reverse 
transcriptase (data not shown). 
Using a specific antibody, Western blot analysis illustrated three major protein 
bands with apparent molecular mass of 27 kDa, 21 kDa and 15 kDa. Since the 
electrophoretic separation was carried out under reducing conditions, these three protein 
bands corresponded to the reported sizes of the monomers of VEGF-Ai 88，VEGF-Ai64 
and VEGF-A 120 respectively. They were present in cultured primary cells, cell lines and 
rat testis with different abundance and expression patterns (Fig.3.3 and 3.4). In line with 
the findings from semi-quantitative analysis of the relative abundance of VEGF-A 
transcripts in different primary cell types together with adjustment of loading based on 
the same amount of total protein, VEGF-A peptide levels appeared to be the highest in 
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Fig.3.1 Immunohistochemical staining of VEGFs in the normal adult rat testes. 
Positive VEGFs immunoreactivity was indicated by the red colour and arrows in tissue 
sections that were counterstained with haematoxylin. In (A-B), immunoreactivity of VEGF-
A was localized in the cytoplasm of Leydig cells (LC)，Sertoli cells (SC) and vascular 
smooth muscle cells (VSMC). In (C-D), immunoreactivity of VEGF-B was concentrated in 
the Leydig cells, which was similar to the immunoreactivity of VEGF-C observed in (E-F). 
In (G-H), immunoreactivity of VEGF-D was mainly localized in the Leydig cells and 
vascular smooth muscle cells, but weaker in the Sertoli cells. (I-L) were the negative 
controls of immunostaining study of VEGF-A, B, C and D respectively, prepared by 
omitting the primary antibody in the staining processes. 
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Fig.3.2 RT-PCR analysis of VEGF-A mRNA expression in rat testis, testicular 
primary cells (A) and testicular cell lines (B). Four major spliced variants of VEGF-A 
mRNA (645bp, 573bp, 513bp and 441 bp) representing VEGF-Aigg, VEGF-A164�VEGF-A144 
and VEGF-A 120 respectively were found in all samples with weaker signals in the testis and 
germ cells. The amount of template used in PCR was adjusted based on prior amplification 
of an internal control, P-actin, with a product size of 643bp (lower panel) which gave similar 
signal intensities for each samples. 
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Fig.3.3 Western blot analysis of VEGF-A protein expression in rat testis and primary 
testicular cells. Equal amount of total protein from each tissue or cell lysate was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-A antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 27 kDa, 21 kDa and 15 kDa representing different isoforms of VEGF-A, 
namely VEGF-Aigg, VEGF-A164 and VEGF-A 120 respectively. The positions of molecular 
mass markers were shown on the left. 
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Fig.3.4 Western blot analysis of VEGF-A protein expression in various testicular cell 
lines. Equal amount of total protein from cell lysate of each testicular cell line was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-A antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 27 kDa, 21 kDa and 15 kDa representing different isoforms of VEGF-A, 
namely VEGF-Aigg, VEGF-A164 and VEGF-A120 respectively. The bands of molecular mass 
of 20 kDa and 19 kDa appeared on cell lines, TM3, TM4, MLTC-1 and R2C might represent 
the native protein that is partially or not glycosylated since the calculated molecular mass of 
VEGF 164 is 19 kDa. The positions of molecular mass markers were shown on the left. 
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the Leydig cell (Fig.3.3). Among the three isoforms, VEGF-Aigg was the most abundant 
in testicular tissues and primary cells (Fig.3.3) while VEGF-Ai64 appeared more 
abundant in cell lines. In Fig.3.4, protein bands of molecular mass of 20 kDa and 19 kDa 
appeared in some cell lines, TM3, TM4，MLTC-1 and R2C. They might represent the 
partially glycosylated and non-glycosylated forms of VEGF-A164. 
In the present and subsequent Western blot analyses, the specificity of the signals 
was confirmed by omitting the incubation with primary or secondary antibody and 
demonstrated their complete disappearance from the blot (data not shown). This would 
avoid misidentification of protein bands that were caused by non-specific binding to the 
primary and secondary antibodies. 
3.1.2 VEGF-B 
In immunohistochemical study, VEGF-B immunoreactivity was localized in the 
interstitium where the Leydig cells were located (Fig.3.1C and D). No immunoreactivity 
was found in Sertoli cells or germ cells as would be expected from the RT-PCR and 
Western blot results. This might be explained by the fact that not all the epitopes were 
retrieved and exposed to specific antibody during the immunostaining process. 
Using specific primers, VEGF-B transcripts were demonstrated in all cultured 
cell types and rat testis in the RT-PCR analysis, and they showed similar expression 
patterns and intensities (Fig.3.5). Two products were found and they corresponded with 
size to those expected from the amplification of VEGF-B 186 and VEGF-B 157 transcripts 
(i.e. 425 bp and 324 bp). RT-PCR results showed that VEGF-B transcripts were 
expressed in Leydig cells and Sertoli cell. 
Western blot analysis showed two major protein bands with apparent molecular 
mass of 35 kDa and 24 kDa in cultured primary cells, cell lines and testis with different 
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abundance and expression patterns (Fig.3.6 and 3.7). Under reducing conditions, 
these two protein bands corresponded in size to those reported for the glycosylated full 
length form of VEGF-B 186 and VEGF-B 16?, respectively. The other protein bands with 
apparent molecular mass of 30 kDa and 19 kDa were probably the proteolytically 
processed forms of the VEGF-B 186 and VEGF-B 16?. Based on the Western blot results, 
VEGF-B 186 peptide (after adjustment of loading based on the same amount of total 
protein) appeared to be the most abundant in the Leydig cell (Fig.3.6). 
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Fig.3.5 RT-PCR analysis of VEGF-B mRNA expression in rat testis, testicular primary 
cells (A) and testicular cell lines (B). Two PCR products corresponding with size to what 
would be expected (i.e. 425 bp and 324 bp) from the amplification of VEGF-B 186 and 
VEGF-B 167 transcripts respectively were obtained. The amount of template used in PCR 
was adjusted based on prior amplification of an internal control, p-actin, with a product size 
of 643bp (lower panel) which gave similar signal intensities for each samples. 
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Fig.3.6 Western blot analysis of VEGF-B protein expression in rat testis and primary 
testicular cells. Equal amount of total protein from each tissue or cell lysate of was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-B antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 35 kDa, 30 kDa and 24 kDa representing different isoforms of VEGF-B. 
The positions of molecular mass markers were shown on the left. 
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Fig.3.7 Western blot analysis of VEGF-B protein expression in various testicular cell 
lines. Equal amount of total protein from cell lysate of each testicular cell line was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-B antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 35 kDa, 30 kDa and 19 kDa representing different isoforms of VEGF-B. 
The positions of molecular mass markers were shown on the left. 
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3.1.3 VEGF-C 
Immunohistochemical staining illustrated that VEGF-C was chiefly localized in 
the Leydig cells (Fig.3.IE and F). Little immunoreactivity was found in Sertoli cells and 
germ cells as would be expected from the RT-PCR and Western blot results. 
Using RT-PCR, VEGF-C mRNA appeared to be present in all cultured cell types 
and rat testis with similar expression patterns and intensities, except in MLTC-1 
(Fig.3.8). The size of the PCR product corresponded to what would be expected (i.e. 253 
bp) from the amplification of VEGF-C transcript. Results demonstrated that Leydig cell 
was the major source of VEGF-C transcripts. 
Western blot analysis showed one major protein band with apparent molecular 
mass of 27 kDa in cultured primary cells, cell lines (except LC540) and testis with very 
different abundance and expression patterns (Fig.3.9 and 3.10). Under reducing 
conditions, this protein band might correspond to the proteolytically processed form of 
VEGF-C. The other protein band with apparent molecular mass of 25 kDa was probably 
a variant of the processed form of VEGF-C peptide. From Western blot (Fig.3.9); 
VEGF-C peptide (after adjustment of loading based on the same amount of total protein) 
appeared to be the most abundant in the Leydig cells, and less in the Sertoli cells. 
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Fig.3.8 RT-PCR analysis of VEGF-C mRNA expression in rat testis, testicular 
primary cells (A) and testicular cell lines (B). A PGR product corresponding in size to 
what would be expected (i.e. 253 bp) from the amplification of VEGF-C transcript was 
found, with a weaker signal seen in MLTC-1 cells. The amount of template used in PGR 
was adjusted based on prior amplification of an internal control, P-actin, with a product size 
of 643bp (lower panel) which gave similar signal intensities for each samples. 
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Fig.3.9 Western blot analysis of VEGF-C protein expression in rat testis and primary 
testicular cells. Equal amount of total protein from each tissue or cell lysate was size 
fractionated on a 12.5% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-C antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 27 kDa and 25 kDa. The positions of molecular mass markers were 
shown on the left. 
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Fig.3.10 Western blot analysis of VEGF-C protein expression in various testicular cell 
lines. Equal amount of total protein from cell lysate of each testicular cell lines was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-C antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 27 kDa and 25 kDa. The positions of molecular mass markers were 
shown on the left. 
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3.1.4 VEGF-D 
In immunohistochemical staining, VEGF-D immunoreactivity was mainly 
localized in the Leydig cells and vascular smooth muscle cells (Fig.S.lG and H). Little 
immunoreactivity was found in Sertoli cells as would be expected from the RT-PCR and 
Western blot results. 
In the RT-PCR analysis, VEGF-D transcript was illustrated in all cultured cell 
types (except in germ cell) and rat testis, and they showed different expression patterns 
and intensities (Fig.3.11). The size of the PCR product corresponded to what would be 
expected (i.e. 233 bp) from the amplification of VEGF-D transcript. RT-PCR results 
illustrated that VEGF-D transcript was expressed in Leydig cell and Sertoli cell. 
In Western blot analysis, the polyclonal antibody recognized proteins with 
apparent molecular mass of 46 kDa, 37 kDa, 30 kDa, 23 kDa and 16 kDa representing 
different processed forms of VEGF-D in cultured primary testicular cells and testis. In 
testicular cell lines, proteins with apparent molecular mass of 30 kDa, 28 kDa, 23 kDa 
and 16 kDa representing different processed forms of VEGF-D were found. They all 
showed different abundance and expression patterns (Fig.3.12 and 3.13). According to 
the Western blot results which were based on the use of the same amount of total protein, 
Leydig cell appeared to be the major source of VEGF-D protein (Fig.3.12). 
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Fig.3.11 RT-PCR analysis of VEGF-D mRNA expression in rat testis, testicular 
primary cells (A) and testicular cell lines (B). A PCR product corresponding in size to 
what would be expected (i.e. 233 bp) form the amplification of VEGF-D transcript was 
found. The amount of template used in PCR was adjusted based on prior amplification of an 
internal control, p-actin, with a product size of 643bp (lower panel) which gave similar 
signal intensities for each samples. 
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Fig.3.12 Western blot analysis of VEGF-D protein expression in rat testis and primary 
testicular cells. Equal amount of total protein from each tissue or cell lysate was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-D antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 46 kDa, 37 kDa, 30 kDa, 23 kDa and 16 kDa representing different 
processed forms of VEGF-D. The positions of molecular mass markers were shown on the 
left. 
75 
LC540 R2C MLTC-1 TM3 TM4 
29 kDa / 】 “ • “ ' i H i . . j M W ^ i b i i ^ < 3 0 kPa 
kDa 
20.1 kDa • 
< 1 6 k D a 
Fig.3.13 Western blot analysis of VEGF-D protein expression in various testicular cell 
lines. Equal amount of total protein from cell lysate of each testicular cell line was size 
fractionated on a 15% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a rabbit polyclonal anti-VEGF-D antibody. The 
blot was then incubated with horseradish peroxidase-conjugated anti-rabbit IgG and 
visualized by the ECL detection system. The antibody recognized proteins with apparent 
molecular mass of 30 kDa, 28 kDa, 23 kDa and 16 kDa representing different processed 
forms of VEGF-D. The positions of molecular mass markers were shown on the left. 
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3.1.5 PIGF 
Owing to no suitable commercially available PIGF antibody that could be used 
for the immunohistochemical staining purpose, this part of study was omitted. 
In RT-PCR analysis, PIGF mRNA was illustrated in all cultured testicular cell 
types and rat testis, and they showed different expression patterns and intensities 
(Fig.3.14). A PCR product corresponding in size to what would be expected (i.e. 383 bp) 
from the amplification of PIGF transcript was found. RT-PCR results demonstrated that 
Leydig cell and Sertoli cell were the sources of PIGF transcripts. 
Western blot analysis showed one major protein band with apparent molecular 
mass of 27 kDa in all cultured cell types and testis with different abundance and 
expression patterns (Fig.3.15 and 3.16). Under reducing conditions, this protein band 
might correspond to the monomer of PIGF. Moreover, another protein band with an 
apparent molecular mass of 45 kDa was also found (Fig.3.15). 
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Fig.3.14 RT-PCR analysis of PIGF mRNA expression in rat testis, testicular primary 
cells (A) and testicular cell lines (B). A PCR product corresponding in size to what would 
be expected (i.e. 383 bp) from the amplification of PIGF transcript, was found. The amount 
of template used in PCR was adjusted based on prior amplification of an internal control, P-
actin, with a product size of 643bp (lower panel) which gave similar signal intensities for 
each samples. 
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Fig.3.15 Western blot analysis of PIGF protein expression in rat testis and primary 
testicular cells. (A) Equal amount of total protein from tissue or cell lysate was size 
fractionated on a 12.5% SDS-polyacrylamide gel under reducing conditions, transferred to a 
PVDF membrane, and immunoblotted with a goat polyclonal anti-PlGF antibody. The blot 
was then incubated with horseradish peroxidase-conjugated anti-goat IgG and visualized by 
the ECL detection system. The antibody recognized proteins with an apparent molecular 
mass of 27 kDa, and 45 kDa. An extra band (28 kDa) detected in Leydig cell lysate might 
represent a glycosylated form of PIGF. The positions of molecular mass markers were 
shown on the left. (B.) A clearer image of the bands of 27 kDa was showed by the same 
blot with longer exposure time. 
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Fig.3.16 Western blot analysis of PIGF protein expression in various testicular cell 
lines. Equal amount of total protein from cell lysate of each cell line was size fractionated 
on a 12.5% SDS-polyacrylamide gel under reducing conditions, transferred to a PVDF 
membrane, and immunoblotted with a goat polyclonal anti-PlGF antibody. The blot was 
then incubated with horseradish peroxidase-conjugated anti-goat IgG and visualized by the 
ECL detection system. The antibody recognized proteins with an apparent molecular mass 
of 27 kDa and 45 kDa. The positions of molecular mass markers were shown on the left. 
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3.2 Effect of Leydig cell depletion on VEGFs expression in the rat testis 
3.2.1 Effect on VEGF-A 
To examine whether Leydig cells were the sole source of the VEGFs, adult rats 
were injected with ethane dimethane sulphonate (EDS) to selectively destroy Leydig 
cells. Four days after EDS treatment, testes from the control group and EDS-treated 
group were removed and prepared for immunohistochemical staining, semi-quantitative 
RT-PCR analysis and Western immunoblotting. 
Injection of EDS resulted in a complete disappearance of Leydig cells at 4 days 
after treatment (Fig.3.17B，D, F and H). This was indicated by fewer numbers of cells 
and enlarged spaces in the testicular interstitium. 
From the immunostaining for VEGF-A, there was a near complete loss of VEGF-
A immunoreactivity in the testicular interstitium, whereas the immunoreactivity in 
Sertoli cells remained strong and intense (Fig.3.17A and B). Besides, vascular smooth 
muscle cells were weakly stained indicating that the expression of VEGF-A in both 
Sertoli cells and vascular smooth muscle cells were not affected by the EDS treatment. 
RT-PCR analysis demonstrated the changes in four spliced variants of VEGF-A 
mRNA: 645bp, 573bp, 513bp and 441bp，representing VEGF-Aigg, VEGF-A164, VEGF-
Ai44 and VEGF-A120 respectively (Fig.3.18A). Combined data of densitometric 
quantification taken from a number of animals indicated that the levels of all four spliced 
variants dropped with VEGF-A 144 reaching a statistical significance (Fig.3.18B). 
Western immunoblotting demonstrated the changes in three isoforms of VEGF-A: 
VEGF-Al88, VEGF-Ai64 and VEGF-A120 (Fig.3.19A). The combined data of 
densitometric quantification taken from a number of animals indicated that VEGF-Ai64 
and VEGF-A120 levels decreased after treatment, and VEGF-Ai 64 showed a complete 
81 
disappearance from the blot (Fig.3.19B). On the contrary, expression of VEGF-Aigg 
remained unaffected by the EDS treatment. These results illustrated that Leydig cells 
would represent the major source of VEGF-A164 and VEGF-A 120 isoforms in the testis. 
3.2.2 Effect on VEGF-B 
Immunohistochemical study showed a complete loss of VEGF-B 
immunoreactivity from the testicular interstitium after EDS treatment, whereas the 
immunoreactivity in Sertoli cells became more apparent after treatment (Fig.3.17C and 
D). 
RT-PCR analysis demonstrated the changes in the levels of the two spliced 
variants of VEGF-B mRNA: 425bp and 324bp, representing VEGF-Bige and VEGF-B167 
respectively (Fig.3.20A). The combined data of densitometric quantification taken from 
a number of animals showed that the levels of both spliced variants dropped with 
statistical significance (Fig.3.20B). 
Western immunoblotting analysis demonstrated the changes in two isoforms of 
VEGF-B, VEGF-B 186 and VEGF-B 16? (Fig.3.21A). The combined data of densitometric 
quantification taken from a number of animals indicated that VEGF-B 186 and VEGF-B 16? 
peptide levels decreased after treatment but only the change in VEGF-B 16? was 
statistically significant (Fig.3.2IB). These results demonstrated that Leydig cell was 
probably a major source of VEGF-B 157 and VEGF-B 186- Comparing to the 
immunostaining study, Sertoli cells could be an alternative source of VEGF-B 186 and 
VEGF-B 167, especially following the destruction of Leydig cells and / or the withdrawal 
of androgen after Leydig cells depletion. 
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Fig.3.17 Immunohistochemical staining of VEGFs in the normal adult rat testes (A, C, 
E and G) and testes of rats at 4 days after ethane dimethane sulphonate (EDS) 
treatment (B, D, F and H). Positive VEGFs immunoreactivity was indicated by the red 
colour and arrows in tissue sections that were counterstained with haematoxylin. Note that 
in testes treated with EDS, there were very few interstitial cells present in the interstitium. 
(A-B) showed the immunoreactivity of VEGF-A before and after treatment. (C-D) showed 
the immunoreactivity of VEGF-B before and after treatment. (E-F) showed the 
immunoreactivity of VEGF-C before and after treatment. (G-H) showed the 
immunoreactivity of VEGF-D before and after treatment. Abbreviations stand for: LC: 
Leydig cells, SC: Sertoli cells and VSMC: vascular smooth muscle cells. 
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Fig.3.18 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-A mRNA expression level in the adult rat testis. (A) Representative semi-
quantitative RT-PCR result showing the effect of treatment on the levels of the four major 
spliced variants of VEGF-A mRNA (645bp, 573bp, 513bp and 441 bp) representing VEGF-
Ai88，VEGF-Ai64, V E G F - A 1 4 4 and V E G F - A 1 2 0 respectively. The amplification of P-actin 
was included as an internal control to adjust the amount of template used. (B) Combined 
data from the densitometric quantification of the signals of four VEGF-A variants, which 
were normalized against the control as 100%. Data represent mean 土 SE of 5 animals per 
control group and 7 animals per treatment group. *P<0.05, by Mann-Whitney rank sum test 
for comparison with the corresponding control. 
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Fig.3.19 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-A protein expression level in the adult rat testis. (A) Representative Western 
blots showed the effect of treatment on the levels of the three VEGF-A isoforms in the 
testes. (B) Combined data from the densitometric quantification of the signals of three 
VEGF-A isoforms, which were normalized against the control as 100%. Data represent 
mean 士 SE of 5 animals per control group and 7 animals per treatment group. *P<0.05, by 
Mann-Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.20 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-B mRNA expression level in the adult rat testis. (A) Representative semi-
quantitative RT-PCR result showing the effect of treatment on the levels of the two spliced 
variants of VEGF-B mRNA (425 bp and 324 bp) representing VEGF-Bige and VEGF-Bigy 
respectively. The amplification of p-actin was included as an internal control to adjust the 
amount of template used. (B) Combined data from the densitometric quantification of the 
signals of two VEGF-B variants, which were normalized against the control as 100%. Data 
represent mean 士 SE of 5 animals per control group and 7 animals per treatment group. 
*P<0.05, by Mann-Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.21 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-B protein expression level in the adult rat testis. (A) A representative Western 
blot showed the effect of treatment on the level of the two VEGF-B isoforms in the testes. 
(B) Combined data from the densitometric quantification of the signals of two VEGF-B 
isoforms, which were normalized against the control as 100%. Data represent mean 土 SE of 
5 animals per control group and 7 animals per treatment group. *P<0.05, by Mann-Whitney 
rank sum test for comparison with the corresponding control. 
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3.2J Effect on VEGF-C 
In immunohistochemical study, a complete loss of VEGF-C immunoreactivity 
from the testicular interstitium was observed after EDS treatment. However, the 
immunoreactivity in Sertoli cells and vascular smooth muscle cells seemed to become 
more apparent after treatment (Fig.3.17E and F). 
RT-PCR analysis demonstrated the changes in the level of the VEGF-C mRNA 
(Fig.3.22A). The combined data of densitometric quantification taken from a number of 
animals did not show any statistical significance in the VEGF-C mRNA level 
(Fig.3.22B). 
On the contrary, a dramatic decrease in the 27 kDa VEGF-C level was 
demonstrated in Western immunoblotting analysis (Fig.3.23A). The combined data of 
densitometric quantification taken from a number of animals showed that VEGF-C 
protein level went down dramatically to near disappearance (Fig.3.23B). These results 
suggested that Leydig cell was a major source of VEGF-C peptide, and in particular the 
27 kDa protein. Results of the immunostaining study showed that despite the dramatic 
fall in the level of the VEGF-C 27 kDa peptide, some VEGF-C immunoreactivities 
remained in Sertoli cells and vascular smooth muscle cells. 
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Fig.3.22 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-C mRNA expression level in the adult rat testis. (A) Representative semi-
quantitative RT-PCR result showing the effect of treatment on the level of the VEGF-C 
mRNA (253 bp). The amplification of p-actin was included as an internal control to adjust 
the amount of template used. (B) Combined data from the densitometric quantification of 
the signals of VEGF-C mRNA, which were normalized against the control as 100%. Data 
represent mean 土 SE of 5 animals per control group and 7 animals per treatment group. 
*P<0.05, by Mann-Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.23 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-C protein expression level in the adult rat testis. (A) A representative Western 
blot showed the effect of treatment on the level of the VEGF-C in the testes. (B) Combined 
data from the densitometric quantification of the signals of VEGF-C, which were normalized 
against the control as 100%. Data represent mean 土 SE of 5 animals per control group and 7 
animals per treatment group. *P<0.05, by Mann-Whitney rank sum test for comparison with 
the corresponding control. 
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3.2.4 Effect on VEGF-D 
Immunohistochemical study showed a complete disappearance of VEGF-D 
immunoreactivity from the testicular interstitium following the selective destruction of 
Leydig cell after EDS treatment, whereas the immunoreactivity in vascular smooth 
muscle cells remained. Besides, immunoreactivity in Sertoli cells seemed to become 
more apparent after treatment (Fig.3.17G and H). 
RT-PCR analysis demonstrated the changes in the level of the VEGF-D mRNA 
(Fig.3.24A). The combined data of densitometric quantification taken from a number of 
animals showed that there was a significant increase in the level of VEGF-D mRNA 
(Fig.3.24B). 
Western immunoblotting analysis demonstrated the changes in the levels of the 
three processed forms of VEGF-D (Fig.3.25A). The combined data of densitometric 
quantification taken from a number of animals showed that the signal intensity for the 37 
kDa form of VEGF-D fell but with no statistically significant level (Fig.3.25B). 
However, EDS treatment did not produce any change in 23 kDa protein level. In 
contrast, the 16 kDa peptide level increased to a significant level indicating that removal 
of Leydig cells hence the source of androgen caused stimulation to certain cell type in 
the testis to produce more 16 kDa peptide of VEGF-D. These results implied that 
Leydig cell might be a source of 37 kDa processed forms of VEGF-D. On the contrary, 
the expression of 16 kDa form of VEGF-D could come from other cellular sources and 
be upregulated following the removal of androgen from destroying the Leydig cells. 
Based on the results of immunostaining study, Sertoli cells and vascular smooth muscle 
cells appeared to be an alternative source of VEGF-D peptides. 
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Fig.3.24 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-D mRNA expression level in the adult rat testis. (A) Representative semi-
quantitative RT-PCR result showing the effect of treatment on the level of the VEGF-D 
mRNA (233 bp). The amplification of p-actin was included as an internal control to adjust 
the amount of template used. (B) Combined data from the densitometric quantification of 
the signals of VEGF-D mRNA, which were normalized against the control as 100%. Data 
represent mean 士 SE of 5 animals per control group and 7 animals per treatment group. 
*P<0.05, by Mann-Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.25 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
VEGF-D protein expression level in the adult rat testis. (A) Representative Western 
blots showed the effect of treatment on the levels of the three VEGF-D isoforms in the 
testes. (B) Combined data from the densitometric quantification of the signals of three 
VEGF-D isoforms, which were normalized against the control as 100%. Data represent 
mean 土 SE of 5 animals per control group and 7 animals per treatment group. *P<0.05, by 
Mann-Whitney rank sum test for comparison with the corresponding control. 
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S.2J Effect on PIGF 
RT-PCR analysis demonstrated the changes in the level of the PIGF mRNA 
(Fig.3.26A). The combined data of densitometric quantification taken from a number of 
animals showed a significant increase was observed in the level of PIGF mRNA 
(Fig.3.26B). 
Western immunoblotting demonstrated that, on the contrary, there was no 
significant change in PIGF protein level before and after treatment (Fig.3.27A). The 
combined data of densitometric quantification taken from a number of animals showed 
that EDS treatment did not produce any statistically significant change in PIGF protein 
level (Fig.3.27B). These results indicated that Leydig cell was not the only source of 
PIGF in the testis. From previous RT-PCR and Western blot results (Fig.3.14, 3.15 and 
3.16)，Sertoli cells could be an alternative source of PIGF. 
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Fig.3.26 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
PIGF mRNA expression level in the adult rat testis. (A) Representative semi-quantitative 
RT-PCR result showing the effect of treatment on the level of the PIGF mRNA (383 bp). 
The amplification of p-actin was included as an internal control to adjust the amount of 
template used. (B) Combined data from the densitometric quantification of the signals of 
PIGF mRNA, which were normalized against the control as 100%. Data represent mean 士 
SE of 5 animals per control group and 7 animals per treatment group. *P<0.05, by Mann-
Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.27 Effect of Leydig cell depletion by ethane dimethane sulphonate (EDS) on 
PIGF protein expression level in the adult rat testis. (A) A representative Western blot 
showed the effect of treatment on the level of the PIGF in the testes. (B) Combined data 
from the densitometric quantification of the signals of PIGF, which were normalized against 
the control as 100%. Data represent mean 土 SE of 5 animals per control group and 7 
animals per treatment group. 
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3,3 Effect of Leydig cell suppression and hCG stimulation on VEGFs expression in 
the rat testis 
The two doses of testosterone implant were used such that the 3 cm implant 
would achieve normal physiological levels of serum testosterone but fail to provide 
adequate hormonal support for normal spermatogenesis, and the 25 cm implant would 
maintain near normal levels of spermatogenesis with a supraphysiological concentration 
of serum testosterone. 
In view of the earlier findings demonstrating Leydig cells to be the source of 
several VEGFs, the following study was carried out to determine how the suppression of 
Leydig cell function would affect the expression of VEGFs in the testis. 
In both 3 cm and 25 cm implant groups, the testis weight decreased significantly 
to reach about 65 % and 90 % of the value found in the control group respectively (Table 
3.1). Such a fall in testis weight mainly represented the loss of spermatogenic activity in 
the testes. Following the injection ofhCG, there was an increasing tendency in the testis 
weight among the normal rats and the testosterone-implanted groups. From histological 
study of the animals bearing testosterone implants of either 3 cm or 25 cm in length 
(Fig.3.28，32, 35，and 38)，many of the interstitial cells were found to regress 
significantly. 
3.3.1 Effect on VEGF-A 
In the control animals, VEGF-A immunostaining was localized mainly in the 
intertubular area within the interstitial cell (Fig.3.28A), although Sertoli cells and 
vascular smooth muscle cells also contained some immunoreactivity. In animals bearing 
the testosterone implants, the interstitial cell population regressed considerably and most 
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of the VEGF-A immunoreactivity was lost from the intertubular area and hence the 
Leydig cells, and present only in Sertoli cells and vascular smooth muscle cells 
(Fig.3.28C and E). After receiving a single injection of hCG’ there was a partial 
recovery of the Leydig cell population in the T-implanted animals as indicated by the re-
appearance of VEGF-A immunoreactivity in the interstitial cells (Fig.3.28D and F). 
In RT-PCR analysis, primers were originally designed to probe for every spliced 
variants of VEGF-A simultaneously, but it did not detect any changes (Fig.3.30.1 and 2). 
This might because of the competition between the spliced variants for the same pair of 
primers. So, an alternative pair of primers was designed (specified for a region that was 
common to every VEGF-A transcripts) to further check that whether there were effects 
on VEGF-A transcripts or not (Fig.3.29.1 and 2). The combined data of densitometric 
quantification taken from six animals per group indicated that VEGF-A dropped in 
animals bearing implants of either 3 cm or 25 cm (Fig.3.29.1B). Injection of hCG did 
not induce an increment in VEGF-A transcript in control and 25 cm implant groups but a 
significant decrement instead (Fig.3.29.2). 
Western immunoblotting analysis demonstrated the changes in three different 
isoforms of V E G F - A , V E G F - A ^ V E G F - A i m and VEGF-Auo (Fig.3.31.1 A) . The 
combined data of densitometric quantification taken from six animals per group 
indicated that V E G F - A , d r o p p e d dramatically in the animals bearing testosterone 
implants of either 3 cm or 25 cm (Fig.3.3UB). On the contrary, expression of VEGF_ 
八哪 appeared e f f e c t e d while VEGF-A,20 showed slight decreases which were not 
statistically significant. These results corresponded to the earlier findings in EDS 
treatment study demonstrating that Leydig cell was likely the major source of 
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— Control Treatment groups 
Testosterone 、 ， . ， ^ ^ ^ 25 cm 
No implant 3 cm 丄)cm 
implant 
— S u b c u t a n e o u s V a l i n e hCG M n e hCG Saline hCG 
injection 
^ 2.122 2.289 2.954 3.283 
Paired testis , + + 
士 士 土 土 工 一 
weight (gram) ^ ^^^ o.l33 0.261* 0.245* 0.112 0.080 
Number of ^ 
animals 
Table 3.1 Effect of Leydig cell suppression followed by hCG sti画lation on the test^ 
weight. Leydig cell suppression was achieved by an eight-week treatment 了池 = 
dose (3 cm)orhigh dose (25 cm) of testosterone-filled subcutaneous implants^ At the end of 
dght weeks, animals were given a single subcutaneous injection of 働 二 h C G ^ d ^ d i e d 
2 days post hCG. Data represent mean ± SE of 6 animals per group. *P<0.05，by Kruskal-
Wallis one-way ANOVA on ranks followed by Dunnett's test for comparison with the 
saline-injected control. 
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Fig.3.28 Immunohistochemical staining of VEGF-A in the testes of normal adult rats 
(A & B) and adult rats that received subcutaneous testosterone-filled silastic implants 
of 3 cm (C & D) or 25 cm (E & F) in length for 8 weeks. Positive VEGFs 
immunoreactivity was indicated by the red colour and arrows in tissue sections that were 
counterstained with haematoxylin. Rats in (B, D & F) were further injected with a single 
dose of 100 IU hCG (or saline for A, C & E) and studied 2 days post-hCG. Note that many 
of the interstitial cells regressed in animals bearing testosterone implants of either 3 cm or 25 
cm in length (C & E). Abbreviations stand for: LC: Leydig cells, SC: Sertoli cells and 
VSMC: vascular smooth muscle cells. 
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Fig.3.29.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on the expression level of the VEGF-A mRNA in the adult 
rat testis. (A) Representative semi-quantitative RT-PCR result showing the effect of 
treatment on VEGF-A transcript level in the testes. The amplification of p-actin was 
included as an internal control to adjust the amount of template used. (B) Combined data 
from the densitometric quantification of the semi-quantitative RT-PCR signals of VEGF-A 
transcript, which were normalized against the control as 100%. Data represent mean 士 SE of 
6 animals per group. *P<0.05, by Kruskal-Wallis one-way ANOVA on ranks followed by 
Dunnett's test for comparison with the corresponding control. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, 13 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig 3.29.2 Effect of a single subcutaneous injection of 100 lU hCG on VEGF-A mRNA 
expression level in the testes of normal adult rats and rats bearing 3 cm or 25 cm 
testosterone implants for 8 weeks. Combined data from the densitometric quantification of 
the semi-quantitative RT-PCR signals of VEGF-A transcript, which were normalized against 
the control as 100%. Data represent mean ± SE of 6 animals per group. *P<0.05，by Mann-
Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.30.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on the expression levels of the three VEGF-A mRNA 
spliced variants expression level in the adult rat testis. (A) Representative semi-
quantitative RT-PCR result showing the effect of treatment on three VEGF-A spliced 
variants levels in the testes. The amplification of p-actin was included as an internal control 
to adjust the amount of template used. (B) Combined data from the densitometric 
quantification of the semi-quantitative RT-PCR signals of VEGF-A spliced variants, which 
were normalized against the control as 100%. Data represent mean 士 SE of 6 animals per 
group. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, T3 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig 3.30.2 Effect of a single subcutaneous injection of 100 lU hCG on the expression 
levels of the three VEGF-A mRNA spliced variants in the testes of normal adult rats 
and rats bearing 3 cm or 25 cm testosterone implants for 8 weeks. Combined data from 
the densitometric quantification of the semi-quantitative RT-PCR signals of three VEGF-A 
spliced variants, which were normalized against the control as 100%. Data represent mean 土 
SE of 6 animals per group. 
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Fig.3.31.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on the expression levels of the three VEGF-A isoforms in 
the adult rat testis. (A) A representative Western blot showed the effect of treatment on 
three VEGF-A isoform levels in the testes. (B) Combined data from the densitometric 
quantification of signal of three VEGF-A isoforms, which were normalized against the 
control as 100%. Data represent mean 士 SE of 6 animals per group. •P<0.05, by Kruskal-
Wallis one-way ANOVA on ranks followed by Dunnett's test for comparison with the 
corresponding control. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, 73 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig 3.31.2 Effect of a single subcutaneous injection of 100 lU hCG on the expression 
levels of VEGF-A isoforms in the testes of normal rats and rats bearing either 3 cm or 
25 cm testosterone implants for 8 weeks. Combined data from the densitometric 
quantification of the signals of three VEGF-A isoforms，which were normalized against the 
control as 100%. Data represent mean 土 SE of 6 animals per group. *P<0.05，by Mann-
Whitney rank sum test for comparison with the corresponding control. 
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V E G F - A i 6 4 isoform (Fig.3.19). Injection of h C G induced increases in V E G F - A i 6 4 
isoform levels in all treatment groups, with statistical significance found in the control 
and 3 cm implant groups. hCG treatment did not cause significant changes in VEGF-
A,88 levels while those of V E G F - A , 2 0 showed decreases in the T-implant groups 
reaching statistical significance in animals bearing 25 cm T-implant (Fig.3.31.2). 
3.3.2 Effect on VEGF-B 
VEGF-B immunoreactivity was localized mainly in the interstitial cells of the 
control animals (Fig.3.32A). In animals bearing the testosterone implants, the interstitial 
cell population regressed noticeably and VEGF-B immunoreactivity was lost from the 
interstitial area (Fig.3.32C and E). After receiving a single dose of hCG，interstitial cell 
population recovered in animals bearing the implants, but to a lesser degree in 25 cm 
implant group (Fig.3.32D and F). 
RT-PCR analysis of VEGF-B transcripts demonstrated the changes in two 
different spliced variants of VEGF-B, VEGF-B.s^ and VEGF-B^ (Fig.3.33.lA). 
Combined data of densitometric quantification taken from six animals per group 
indicated no significant changes in the levels ofVEGF-B.s6 and V E G F - B . . v transcripts 
(Fig.3.33.1B). Injection o fhCG induced small increases in VEGF-B transcript levels in 
control animals, reaching statistical significance for VEGF-B186 (Fig.3.33.2). 
Western immunoblotting analysis demonstrated the changes in two isoforms of 
VEGF-B, VEGF-B186 and VEGF-B167 (Fig.3.34.1A). The combined data of 
densitometric quantification taken from six animals per group indicated that VEGF-B 
isoforms dropped generally in two implant groups while only VEGF-B167 dropped to a 
significant level in the animals bearing testosterone implants of 25 cm (Fig.3.34.1B). 
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Fig.3.32 Immunohistochemical staining of VEGF-B in the testes of normal adult rats 
(A & B) and adult rats that received subcutaneous testosterone-filled silastic implants 
of 3 cm (C & D) or 25 cm (E & F) in length for 8 weeks. Positive VEGFs 
immunoreactivity was indicated by the red colour and arrows in tissue sections that were 
counterstained with haematoxylin. Rats in (B，D & F) were further injected with a single 
dose of 100 lU hCG (or saline for A，C & E) and studied 2 days post-hCG. Note that many 
of the interstitial cells regressed in animals bearing testosterone implants of either 3 cm or 25 
cm in length (C & E). Abbreviations stand for: LC: Leydig cells, SC: Sertoli cells and 
VSMC: vascular smooth muscle cells. 
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Fig.3.33.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on two VEGF-B mRNA spliced variants expression level in 
the adult rat testis. (A) Representative semi-quantitative RT-PCR result showing the effect 
of treatment on two VEGF-B transcripts level in the testes. The amplification of p-actin was 
included as an internal control to adjust the amount of template used. (B) Combined data 
from the densitometric quantification of the semi-quantitative RT-PCR signals of VEGF-B 
transcripts, which were normalized against the control as 100%. Data represent mean 土 SE 
of 6 animals per group. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, 73 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig. 3 . 3 3 . 2 Effect of a single subcutaneous injection of 100 lU hCG on the expression 
levels of the two spliced variants of VEGF-B mRNA in the testes of normal adu t rat 
and rats bearing 3 cm or 25 cm testosterone implants for 8 weeks. Combu^d^ta frcn二 
the densitometric quantification of the semi-quantitative RT-PCR signals of two VEGF-B 
spliced variants, which were normalized against the control as lOO�/�. Data represent mean ± 
SE of 6 animal； per group. *P<0.05, by Mann-Whitney rank 讓 test for comparison with 
the corresponding control. 
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Fig.3.34.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on the expression levels of the two VEGF-B isoforms in the 
adult rat testis. (A) A representative Western blot showed the effect of treatment on two 
VEGF-B isoform levels in the testes. (B) Combined data from the densitometric 
quantification of signal of two VEGF-B isoforms, which were normalized against the control 
as 100%. Data represent mean 士 SE of 6 animals per group. *P<0.05, by Kruskal-Wallis 
one-way ANOVA on ranks followed by Dunnett's test for comparison with the 
corresponding control. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, T3 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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FiP 3.34.2 Effect of a single subcutaneous injection of 100 lU hCG on the expression 
ievd of V E G F - B isoforms in the testes of normal adult rats and rats b e a r m g e i t h e r 3 
c = r 25 cm testosterone implants for 8 weeks. Combined data from the densitome nc 
q L t m c a t i o n of the signals of two VEGF-B isoforms, wh.ch were n o = i z e d 
control as 100%. Data represent mean ± SE of 6 animals per group. *P<0.05，by Mann 
Whitney rank sum test for comparison with the corresponding control. 
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On the other hand, expression of VEGF-B,86 was little affected by the suppression of 
Leydig cell function by T-implants. Injection of hCG caused an overall significant 
increase in VEGF-B186 peptide levels, but only in the control and 3 cm implant groups 
(Fig.3.34.2). VEGF-B 167 seemed not to be affected by hCG treatment. 
3.3.3 Effect on VEGF-C 
In the control animals, VEGF-C immunostaining was localized chiefly in the 
interstitial cells and hence the Leydig cells (Fig.3.35A). Immunoreactivity in Sertoli 
cells and vascular smooth muscle cells was not observed. Interstitial cell population 
regressed considerably in animals bearing the testosterone implants and nearly all of the 
VEGF-C immunoreactivity was lost from the intertubular area (Fig.3.35C and E). After 
receiving a single dose ofhCG, interstitial cell population in animals bearing implants 
showed recovery with the return of VEGF-C immunoreactivity (Fig.3.35D and F). 
RT-PCR analysis demonstrated the changes in VEGF-C mRNA levels 
(Fig.3.36.1 A). Combined data of densitometric quantification taken from six animals per 
group demonstrated a decline of expression of VEGF-C transcripts in animals bearing 25 
cm implant (Fig.3.36.1B). Injection of hCG generally increased VEGF-C transcripts 
expression in control and treatment groups but a significant increase was only noted in 
the 25 cm implant group (Fig.3.36.2). 
Western immunoblotting analysis demonstrated a marked decrease in VEGF-C 
peptide levels (Fig.3.37.1A) in the testes of animals bearing testosterone implants of 
either 3 cm or 25 cm (indicated by the combined data of densitometric quantification 
taken from six animals per group) (Fig.3.37.1B). These results correlated to the earlier 
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Fig.3.35 Immunohistochemical staining of VEGF-C in the testes of normal adult rats 
(A & B) and adult rats that received subcutaneous testosterone-filled silastic implants 
of 3 cm (C & D) or 25 cm (E & F) in length for 8 weeks. Positive VEGFs 
immunoreactivity was indicated by the red colour and arrows in tissue sections that were 
counterstained with haematoxylin. Rats in (B, D & F) were further injected with a single 
dose of 100 lU hCG (or saline for A，C & E^ and studied 2 days post-hCG. Note that many 
of the interstitial cells regressed in animals bearing testosterone implants of either 3 cm or 25 
cm in length (C & E). Abbreviations stand for: LC: Leydig cells, SC: Sertoli cells and 
VSMC: vascular smooth muscle cells. 
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Fig.3.36.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on the expression level of the VEGF-C mRNA in the adult 
rat testis. (A) Representative semi-quantitative RT-PCR result showing the effect of 
treatment on VEGF-C transcript level in the testes. The amplification of P-actin was 
included as an internal control to adjust the amount of template used. (B) Combined data 
from the densitometric quantification of the semi-quantitative RT-PCR signals of VEGF-C 
transcript, which was normalized against the control as 100%. Data represent mean 士 SE of 
6 animals per group. •P<0.05, by Kruskal-Wallis one-way ANOVA on ranks followed by 
Dunnett's test for comparison with the corresponding control. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, T3 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig.3.36.2 Effect of a single subcutaneous injection of 100 lU hCG on the expression 
level of the VEGF-C mRNA in the testes of normal adult rats and rats bearmg 3 cm or 
25 m testosterone implants for 8 weeks. Combined data from the densitometnc 
qLt i f ica t ion of the semi-quantitative RT-PCR signals of VEGF-C tr^scnpt which were 
normalized against the control as 100%. Data represent mean 士 SE of 6 animals per group. 
*P<0.05, by Mann-Whitney rank sum test for comparison with the corresponding control. 
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Fig.3.37.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on the expression level of the VEGF-C protein in the adult 
rat testis. (A) A representative Western blot showed the effect of treatment on VEGF-C 
protein level in the testes. (B) Combined data from the densitometric quantification of signal 
of VEGF-C, which were normalized against the control as 100%. Data represent mean 士 SE 
of 6 animals per group. *P<0.05, by Kruskal-Wallis one-way ANOVA on ranks followed 
by Dunnett's test for comparison with the corresponding control. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, T3 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig.3.37.2 Effect of a single subcutaneous injection of 100 lU hCG on the expression 
level of VEGF-C protein in the testes of normal adult rats and rats bearing either 3 cm 
or 25 cm t e s t o s t L n e implants for 8 weeks. Combined data from the d e n s i t o i ^ ^ 
quantification of the signals of VEGF-C, which were normalized against the control as 
100%. Data represent mean 土 SE of 6 animals per group. *P<0.05, by Mann-Whitney rank 
sum test for comparison with the corresponding control. 
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findings in EDS treatment study that Leydig cell was proposed to be the major source of 
VEGF-C peptide (Fig.3.23). Injection o f h C G caused inconsistent changes in VEGF-C 
expression with a significant decrease in the 3 cm implant group (Fig.3.37.2). 
3.3.4 Effect on VEGF-D 
VEGF-D immunoreactivity was localized mainly in the Leydig cells and vascular 
smooth muscle cells of the blood vessels of the control animals (Fig.3.38A), although 
Sertoli cells also contained some immunoreactivity. In animals bearing the testosterone 
implants, the interstitial cell population regressed considerably and most of the VEGF-D 
immunoreactivity was lost from the interstitial cells, except the one present in vascular 
smooth muscle cells (Fig.3.38C and E). After receiving a single injection of hCG, 
regression of interstitial cell population was recovered in animals bearing the implants， 
but such recovery was to a lesser extent in 25 cm implant group (Fig.3.38D and F), and 
in comparison, the expression of VEGF-D in Sertoli cells apparently became more 
obvious. 
RT-PCR analysis demonstrated the changes in of VEGF-D transcripts 
(Fig.3.39.1 A). Combined data of densitometric quantification taken from six animals per 
group demonstrated a tendency of decline of expression of VEGF-D transcripts in the 
testosterone implanted groups despite of statistical insignificance (Fig.3.39.1B). 
Injection o f h C G generally induced an increment in VEGF-D transcripts in control and 
treatment groups, and among them, a significant increase was only noted in the 3 cm and 
25 cm implant groups (Fig.3.39.2). 
Western immunoblotting analysis demonstrated the changes in three isoforms of 
VEGF-D (Fig.3.40.1A). The combined data of densitometric quantification taken from 
six animals per group indicated that the 16 kDa peptide increased significantly in the 
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animals bearing testosterone implants of either 3 cm or 25 cm (Fig.3.40.1B). However, 
there were no significance both in the 37 kDa and 23 kDa peptides. These results could 
correlate with the earlier findings in EDS treatment study that the removal of androgen 
caused the 16 kDa peptide level to rise (Fig.3.25). Injection ofhCG caused a general 
increasing trend in VEGF-D isoforms, but statistical significance were only found in the 
23 kDa peptide of the control group and 16 kDa peptide of the 3 cm implant group 
(Fig.3.40.2). 
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Fig.3.38 Immunohistochemical staining of VEGF-D in the testes of normal adult rats 
(A & B) and adult rats that received subcutaneous testosterone-filled silastic implants 
of 3 cm (C & D) or 25 cm (E & F) in length for 8 weeks. Positive VEGFs 
immunoreactivity was indicated by the red colour and arrows in tissue sections that were 
counterstained with haematoxylin. Rats in (B, D & F) were further injected with a single 
dose of 100 lU hCG (or saline for A, C & E) and studied 2 days post-hCG. Note that many 
of the interstitial cells regressed in animals bearing testosterone implants of either 3 cm or 25 
cm in length (C & E). Abbreviations stand for: LC: Leydig cells, SC: Sertoli cells and 
VSMC: vascular smooth muscle cells of the blood vessels. 121 
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Fig.3.39.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on VEGF-D mRNA expression level in the adult rat testis. 
(A) Representative semi-quantitative RT-PCR result showing the effect of treatment on 
VEGF-D transcript level in the testes. The amplification of P-actin was included as an 
internal control to adjust the amount of template used. (B) Combined data from the 
densitometric quantification of the semi-quantitative RT-PCR signals of VEGF-D transcript, 
which was normalized against the control as 100%. Data represent mean 土 SE of 6 animals 
per group. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, T3 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig.3.39.2 Effect of a single subcutaneous injection of 100 lU hCG f : 
eight-week treatment of testosterone-filled implants on VEGF-D mRNA expression 
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Fig.3.40.1 Effect of Leydig cell suppression by eight-week treatment of subcutaneous 
testosterone-filled implants on VEGF-D protein isoforms expression level in the adult 
rat testis. (A) A representative Western blot showed the effect of treatment on three VEGF-
D isoforms level in the testes. (B) Combined data from the densitometric quantification of 
signal of three VEGF-D isoforms, which were normalized against the control as 100%. Data 
represent mean 土 SE of 6 animals per group. *P<0.05，by Kruskal-Wallis one-way ANOVA 
on ranks followed by Dunnett's test for comparison with the corresponding control. 
Abbreviations stand for: C: control, H: rats received a single injection of 100 lU hCG and 
examined at 2 days post-injection, T3 & T25: rats received 3 cm or 25 cm subcutaneous 
testosterone-filled implants for 8 weeks, and T3H & T25H: T-implant bearing rats injected 
with a single dose of 100 lU hCG and studied 2 days post-hCG injection. 
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Fig.3.40.2 Effect of a single subcutaneous injection of 100 I&hCG f o ^ r t l L d T r ^ T s 
r T a L ； of the signals of three VEGF-D isoforms，wh.ch were n o = i z e a g a i n : = 
L t r o l as 100%. Data represent mean ± SE of 6 animals per group. *P<0.05，by Mann-
Whitney rank sum test for comparison with the corresponding control. 
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4. Discussion 
Early studies have revealed that VEGF-A is synthesized in the testis and 
predominantly associated with the Leydig cells (Au et aL’ 1997; Collin & Bergh, 
1996; Korpelainen et al., 1998; Shweiki et aL, 1993; Wan et aL, 1996)，however the 
control of its expression is largely unknown. Four other members of the VEGF 
family，PIGF, VEGF-B, VEGF-C and VEGF-D, have been then identified to share 
structural and functional similarity in expression patterns, receptor specificity and 
cellular function (Joukov et al., 1996; Lee et al. 1996; Leung et aL, 1989; Li & 
Eriksson, 2001; Maglione et aL. 1991; Olofsson et aL, 1996a; Olofsson et al, 1999). 
Furthermore, expression of their receptors (VEGFR-l, VEGFR-2 and VEGFR-3) has 
been identified in rat and human tissues (Galland et aL, 1993; Pajusola et al., 1993; 
Shibuya et aL, 1990; Sandner et aL, 1997; Terman et aL, 1991; Wen et al., 1998; 
Yamane et al., 1994). In the present study, we demonstrated the expression and 
localization of VEGF-A, PIGF, VEGF-B, VEGF-C and VEGF-D in the rat testis and 
they expressed in both Leydig cells and Sertoli cells. These findings would suggest 
that the VEGF family members (VEGFs) may have a complex interaction with each 
other in autocrine or paracrine manner in the testis. 
In the present study, apart from VEGF-A, four other members of the VEGF 
family (PIGF, VEGF-B, VEGF-C and VEGF-D) have been demonstrated to be 
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present in the testis and they are inimunolocalized mainly to Leydig cells. Using 
RT-PCR and Western immunoblotting, these peptides were also found to be expressed 
in Sertoli cells. 
Since the four members of the VEGF family (PIGF, VEGF-B, VEGF-C and 
VEGF-D) have been discovered for about a decade only, very few studies have been 
done on rat tissues. As a result, deduction of the molecular weight of these peptides 
in rat would largely depend on the findings from human and mouse, and the 
specificity of the purchased antibodies. 
The molecular weight of PIGF as revealed by Western blotting in the present 
study was 27 kDa. This finding is close to the study by DiPalma et aL (1996), where 
the molecular weight of mouse PIGF was found to be about 30 kDa. DiPalma et aL 
(1996) pointed out that the mouse PIGF sequences showed • identity to the rat 
PIGF sequences. Although the murine PIGF protein was found with a relative 
molecular mass about 30 kDa, its molecular 麵 would still depend on the amount of 
N-glycosylation on its 17.8 kDa native protein (DiPalma et aL, 1996). So, different 
amount of glycosylation would be one possible explanation for this size discrepancy 
between the reported size and the one found in the present study. F u r t h e r 
differences in the protein sequences between rat and mouse would be another reason 
for the size discrepancy. 
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The molecular weights ofVEGF-B,86 and VEGF-B167 isoforms were found to be 
35 kDa and 24 kDa respectively in the present study. According to the studies by 
Olofsson et al., the mouse and human VEGF-B genes were almost identical (Olofsson 
et al.’ 1996a, b). Their molecular masses were found to be 32 kDa and 21 kDa 
respectively for VEGF-B,86 and V E G F - B , i n mouse (Olofsson et al,, 1996a，b). 
Both the secreted f o 讓 of VEGF-B (VEGF-B.sc and V E G F - B 167) were found to be 
modified by 0-linked or N-linked glycosylation (Olofsson et al., 1996a，b). So, the 
size discrepancy between the reported sizes and those found in the present study could 
be resulted from differences in the protein sequences between rat and mouse, and 
amount of 0-linked or N-linked glycosylation. 
For VEGF-C, molecular weight of its peptide was found to be 27 kDa in the 
Western blotting. According to Kukk et al. (1996)，VEGF-C was reveled as a 
secreted polypeptide of 30 to 32 kDa in weight. Kukk et aL (1996) also 
demonstrated that the pattern of proteolytic processing of VEGF-C in mouse and 
human was nearly identical. So，discr印ancy between the reported size and the size 
found in the present study could be resulted from different protein sequences between 
rat and mouse, level of proteolytic processing and amount of glycosylation. 
Similar to VEGF-C, VEGF-D is synthesized as a preproprotein requiring 
proteolytic processing in both the N- and C-terminal regions for activity, and the fully 
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processed growth factor is a non-covalent dimer (Orlandini et al, 1996). The 37 
kDa peptide reveled in the Western blotting was actually the unprocessed precursor of 
VEGF-D. Moreover, according to the study by Orlandini et al (1996)，the 23 kDa 
and 16 kDa peptides would probably be two proteolytic processed forms of VEGF-D, 
though the discrepancy could be because of the different protein sequences between 
mouse and rat. 
Presence of VEGF-C and VEGF-D in the Leydig cells indicates their possible 
involvement in the development of the testicular lymphatic vessels through binding to 
VEGFR-3 and regulating vascular functions through VEGFR-2 present on testicular 
vascular endothelium. 
Similar to VEGF-A, VEGF-D was also immunolocalized to vascular smooth 
muscle cells. VEGF-D has been shown to be angiogenic to endothelial cells， 
although it is less potent than VEGF-A (Achen et al., 1998; Marconcini et al., 1999; 
Orlandini et 1996). This may imply that VEGF-D is also involved in regulating 
the growth and maintenance of the testicular blood vessels. 
In this study, we demonstrated the existence of VEGF-B and PIGF that they may 
form heterodimers with VEGF-A when co-expressed in the same tissue or cell (Cao 过 
al., 1996; DiSalvo et al.’ 1995; Olofsson et aL, 1996a，b). Such overlapping 
expression of VEGF-A, VEGF-B and PIGF in the testis suggests that 
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VEGF-A/VEGF-B or VEGF-A/PIGF heterodimers may formed naturally within the 
testis to affect the bioavailability of VEGF-A and its action on vascular endothelial 
cells and other non-endothelial cell types. 
The present study further demonstrated that destroying the Leydig cells by 
ethane dimethane sulphonate (EDS) treatment decreased the levels ofVEGF-A.64 and 
VEGF-Ano isoforms, VEGF-B,S6 and VEGF-B,.v isoforms，VEGF-C peptides, but 
increased the levels of VEGF-D (mRNA and 16 kDa isoform) and PIGF. These 
results suggest that Leydig cells are representing the primary source of VEGF-Ai64 
and VEGF-A.,0 isoforms, VEGF-B,S6 and VEGF-B.,. isoforms and VEGF-C. On 
the contrary, VEGF-A.s isoform, VEGF-D 37 kDa, 23 kDa and 16 kDa isoforms and 
PIGF are not mainly produced by Leydig cells. 
VEGF-D was recently shown to be androgen-repress ible (Ezer & Robaire，2003). 
So, removal of Leydig cells in the treatment caused decline in circulating androgen 
that in turn induced an increase in VEGF-D 16 kDa isoform from other testicular cells 
and tissue (probably the vascular smooth muscle cells and Sertoli cells as illustrated in 
the immunohistochemical staining study). In other words, there were other major 
sources of VEGF-D 16 kDa and PIGF peptides besides the Leydig cells, and / or their 
expression was repressed by androgen. 
The vascular effects of hCG on the testis has-been well-documented. In adult 
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rats, the testes respond to a single injection ofhCG with a decrease followed by an 
increase in blood flow, and an inflammation-like reaction of polymorphonuclear 
leukoctes infiltration and vascular permeability increase (Setchell & Sharpe，1981; 
Widmark et al.’ 1986). The last effect results in the accumulation of interstitial fluid 
which could explain why the testis weight of these animals was significantly 
increased at 2 days post-hCG. Since no LH/hCG receptors have been found in 
testicular blood vessels or on the surface of vascular endothelial cells. Thus the 
vascular effects of hCG are likely to have been produced indirectly through the 
release of other mediators from within the testis. 
Chronic suppression of Leydig cells by subcutaneous testosterone-filled implants 
induced a declining expression on VEGF-A mRNA, VEGF-A..4 protein isoform, 
VEGF-B167 protein isoform, VEGF-C mRNA and protein. In contrast to EDS 
treatment, Leydig cell suppression did not result in significant decreases m the levels 
of VEGF mRNA levels. Only VEGF-A.,4 peptide levels fell in both EDS treatment 
and Leydig cell suppression. Besides, results on VEGF-B... isoform and VEGF-C 
correlated with the findings in EDS treatment quite well and suggested that Leydig 
cells could be the source of these peptides. 
The present study confirms that a single injection of 100 lU hCG induces an 
increased synthesis of VEGF-A,,4 in testes of normal rats and those receiving 
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testosterone implants in 2-days post-hCG, which is in line with the observation of 
Haggstrom Rudolfsson et al (2003). Leydig cells would be the major cell type 
responsible for producing such physiological response because of, first, hCG (a LH 
agonist) binds selectively to Leydig cells; second, Leydig cell was proved to be the 
major source of VEGF-A,m in the previous EDS treatment study. Besides，we have 
further demonstrated that injection of hCG induced increases in VEGF-B186 mRNA 
and protein, VEGF-C mRNA and VEGF-D mRNA and protein. So, expression of 
the above VEGF family members was shown to be hormonally regulated by hCG. 
To summarize all the findings in the present study, two points can be drawn. 
First, there were discrepancies in the changes of VEGF-related peptide mRNA and 
protein levels following EDS treatment (removal of Leydig cells and androgen) and 
suppression of Leydig cell function using T-implants. Second, angiogenic factor(s) 
responsible for mediating hCG-induced increase in endothelial cell proliferation 
remained unclear. Consistent increases were observed only for VEGF-A164, but the 
absolute levels did not appear to correlate with the degree of endothelial cell 
proliferation. Based on these findings, further studies will be required to examine 
other parameters, first, the metalloproteases or heparinase which may play a role in 
the release of these VEGF-related peptides from their association with heparan 
sulphate proteoglycan on cell surface and extracellular matrix; second, the expression 
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of other pro-angiogenic or anti-angiogenic factors. 
In conclusion, expression of various new VEGF family members，including PIGF, 
VEGF-B, VEGF-C and VEGF-D, was demonstrated in the testis (mainly found in 
Leydig cells and Sertoli cells). Leydig cell was demonstrated to be a major source of 
V E G F - A i 6 4 and VEGF -A ,20 isoforms, VEGF-B,86 and VEGF-B167 isoforms. 
Expression of VEGF-D (mRNA and 16 kDa isoform) and PIGF was demonstrated to 
be androgen repressible. Besides, expression of VEGF-Aim was demonstrated to be 
hormonally regulated by hCG. 
133 
5. References 
Aase K. (2001) On Vascular Endothelial Growth Factor B and Platelet-Derived Growth 
Factor C Two members of the VEGF/PDGF family of growth factors. 
Department of Cellular and Molecular Biology, Karolinska Institute, Stockholm, 
Sweden. Ref Type: Thesis/Dissertation 
Achen M. G., Jeltsch M.，Kukk E.，Makinen T.，Vitali A., Wilks A. R, Alitalo K.’ & 
Stacker S. A. (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand 
for the tyrosine kinases VEGF receptor 2 (Flkl) and VEGF receptor 3 (Flt4). 
Proc.Natl.Acad.Sci.U.S.A 95: 548-553. 
Alon T.，Hemo I., Itin A.，Pe'er J.，Stone J., & Keshet E. (1995) Vascular endothelial 
growth factor acts as a survival factor for newly formed retinal vessels and has 
implications for retinopathy of prematurity. NatMed. 1： 1024-1028. 
Au C. L.，Chung H. S.，Pang H. C.，& Chan L. F. (1996) Human chorionic gonadotrophin 
(hCG)-induced endothelial cell proliferation in adult rat testes and its dependence 
on the presence of Leydig cells. J.Physiol 497: 7 IP. 
All C. L.，Chan L. F.，Wan W. C .， & Lee W. M. (1997) Localization of vascular 
endothelial growth factor (VEGF) in rodent testis. InU.Androl 20: 72. 
Au C. L.，W u H. W., Kwan H. Y.，Chan L. F .，& Lee W. M. (1998) Involvement of 
vascular endothelial growth factor (VEGF) in Leydig cell-macrophage interaction 
in rat testes. J.Endocrinol 159: 62. 
Baldwin M. E.，Catimel B.，Nice E. C.，Roufail S.，Hall N. E.，Stenvers K. L., Karkkainen 
M. J., Alitalo K.，Stacker S. A” & Achen M. G. (2001) The specificity of receptor 
binding by vascular endothelial growth factor-d is different in mouse and man. 
J.BiolChem. 276: 19166-19171. 
134 
Barleon B., Sozzani S.，Zhou D., Weich H. A.，Mantovani A., & Marme D. (1996) 
Migration of human monocytes in response to vascular endothelial growth factor 
(VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343. 
Bergh A. (1985) Effect of cryptorchidism on the morphology of testicular macrophages: 
evidence for a Leydig cell-macrophage interaction in the rat testis. Int.J.Androl 8: 
86-96. 
Bergh A., Damber J. E.，& van Rooijen N. (1993) Liposome-mediated macrophage 
depletion: an experimental approach to study the role of testicular macrophages in 
the rat. J.Endocrinol. 136: 407-413. 
Breier G.，Damert A., Plate K. H.，& Risau W. (1997) Angiogenesis in embryos and 
ischemic diseases. Thromb.Haemost. 78: 678-683. 
Cao Y.’ Chen H.，Zhou L., Chiang M. K” Anand-Apte B.，Weatherbee J. A., Wang Y., 
Fang F.，Flanagan J. G.’ & Tsang M. L. (1996) Heterodimers of placenta growth 
factor/vascular endothelial growth factor. Endothelial activity，tumor cell 
expression, and high affinity binding to Flk-l/KDR. J.Biol.Chem. 271: 3154-3162. 
Cao Y., Ji W. R., Qi P., Rosin A., & Cao Y. (1997) Placenta growth factor: identification 
and characterization of a novel isoform generated by RNA alternative splicing. 
Biochem.Biophys.Res.Coimnun. 235: 493-498. 
Cao Y.，Linden P., Famebo J., Cao R., Eriksson A., Kumar V., Qi J. H., Claesson-Welsh 
L.，& Alitalo K. (1998) Vascular endothelial growth factor C induces angiogenesis 
in vivo. Proc.Natl.Acad.Sci.U.S.A 95: 14389-14394. 
Chilov D., Kukk E.，Taira S., Jeltsch M.’ Kaukonen J.，Palotie A., Joukov V., & Alitalo K. 
(1997) Genomic organization of human and mouse genes for vascular endothelial 
growth factor C. J.Biol.Chem. 272: 25176-25183. 
135 
Collin O. & Bergh A. (1996) Leydig cells secrete factors which increase vascular 
permeability and endothelial cell proliferation. IntJ.Androl 19: 221-228. 
Conway E. M., Collen D.，& Carmeliet P. (2001) Molecular mechanisms of blood vessel 
growth. Cardiovasc.Res. 49: 507-521. 
de Vries C” Escobedo J. A.，Ueno H.’ Houck K.，Ferrara N .，& Williams L. T. (1992) 
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. 
Science 255:989-991. 
DiPalma T.，Tucci M.’ Russo G.，Maglione D.，Lago C. T., Romano A., Saccone S.，Delia 
V. G.，De Gregorio L.，Dragani T. A., Viglietto G.，& Persico M. G. (1996) The 
placenta growth factor gene of the mouse. Mamm. Genome 7: 6-12. 
DiSalvo J., Bayne M. L.，Conn G.’ Kwok P. W.，Trivedi P. G.，Soderman D. D.，Palisi T. 
M.，Sullivan K. A., & Thomas K. A. (1995) Purification and characterization of a 
naturally occurring vascular endothelial growth factor: placenta growth factor 
heierodimcY. J.BioLChem. 270: 7717-7723. 
Dissen G. A., Lara H. E.，Fahrenbach W. H.，Costa M. E.，& Ojeda S. R. (1994) 
Immature rat ovaries become revascularized rapidly after autotransplantation and 
show a gonadotropin-dependent increase in angiogenic factor gene expression. 
Endocrinology 134: 1146-1154. 
D u m o n t D. J.，Jussila L.，Taipale J.，Lymboussaki A., Mustonen T.，Pajusola K., 
Breitman M., & Alitalo K. (1998) Cardiovascular failure in mouse embryos 
deficient in VEGF receptor-3. Science 282: 946-949. 
E n h o l m B.，Paavonen K.，Ristimaki A.，Kumar V.，Gunji Y.，Klefstrom J., Kivinen L., 
Laiho M.，Olofsson B.，Joukov V.，Eriksson U.，& Alitalo K. (1997) Comparison of 
VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors， 
oncoproteins and hypoxia. Oncogene 14: 2475-2483. 
136 
Ergun S.，Kilic N.，Fiedler W., & Mukhopadhyay A. K. (1997) Vascular endothelial 
growth factor and its receptors in normal human testicular tissue. Mol.Cell 
Endocrinol. 131: 9-20. 
Ezer N. & Robaire B. (2003) Gene expression is differentially regulated in the 
epididymis after orchidectomy. Endocrinology 144: 975-988. 
Fawcett D. W.，Neaves W. B.，& Flores M. N. (1973) Comparative observations on 
intertubular lymphatics and the organization of the interstitial tissue of the 
mammalian testis. BioLReprod. 9: 500-532. 
Ferrara N. (1996) Vascular endothelial growth factor. Eur. J.Cancer 32A: 2413-2422. 
Ferrara N. & Davis-Smyth T. (1997) The biology of vascular endothelial growth factor. 
Endocr.Rev. 18:4-25. 
Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. 
Nat.Med. 1:27-31. 
Fuh G.’ Li B.，Crowley C.，Cunningham B.，& Wells J. A. (1998) Requirements for 
binding and signaling of the kinase domain receptor for vascular endothelial growth 
factor. J.BiolChem. 273: 11197-11204. 
Fujimoto J.，Ichigo S.’ Hirose R., Sakaguchi H.，& Tamaya T. (1998) Expressions of 
vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial 
cancers. Cancer Lett. 134: 15-22. 
Galland F.，Karamysheva A.，Pebusque M. J.，Borg J. P., Rottapel R., Dubreuil P., Rosnet 
0 ” & Bimbaum D. (1993) The FLT4 gene encodes a transmembrane tyrosine 
kinase related to the vascular endothelial growth factor receptor. Oncogene 8: 
1233-1240. 
137 
Geva E. & Jaffe R. B. (2000) Role of vascular endothelial growth factor in ovarian 
physiology and pathology. FertilSteril 74: 429-438. 
Gleadle J. M.，Ebert B. L.，Firth J. D.，& Ratdiffe P. J. (1995) Regulation of angiogenic 
growth factor expression by hypoxia, transition metals, and chelating agents. 
AmJ.Physiol 268: C1362-C1368. 
Gness i L.，Emidi A. , Jannini E. A ” Carosa E.，Maroder M.，Arizzi M.，Ulisse S.，& Spera 
G. (1995) Testicular development involves the spatiotemporal control of PDGFs 
and PDGF receptors gene expression and action. J.CellBiol 131: 1105-1121. 
Gorczynska E. & Handelsman D. J. (1993) Requirement for transmembrane sodium flux 
in maintenance of cytosolic calcium levels in rat Sertoli cells. AmJ.Physiol 264: 
E863-E867. 
Gordon J. D.，Mesiano S., Zaloudek C. J.，& Jaffe R. B. (1996) Vascular endothelial 
growth factor localization in human ovary and fallopian tubes: possible role in 
reproductive function and ovarian cyst formation. J.Clin.EndocnnolMetab 81: 
353-359. 
Haggstrom Rudolfsson S.，Wikstrom P., Jonsson A., Collin O.，& Bergh A. (2003) 
Hormonal Regulation and Functional Role of Vascular Endothelial Growth Factor 
A in the Rat Testis. BiolReprod. (in press). 
Hauser S. & Weich H. A. (1993) A heparin-binding form of placenta growth factor 
(PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. 
Growth Factors 9: 259-268. 
Hiratsuka S.’ Minowa 0” Kuno J., Noda T.，& Shibuya M. (1998) Flt-1 lacking the 
tyrosine kinase domain is sufficient for normal development and angiogenesis in 
mice. Proc.NatUcad.Sci.U.S.A 95: 9349-9354. 
138 
Houck K. A., Ferrara N.，Winer J., Cachianes G.，Li B .，& Leung D. W. (1991) The 
vascular endothelial growth factor family: identification of a fourth molecular 
species and characterization of alternative splicing of RNA. MolEndocrinol 5: 
1806-1814. 
Hughes D. C. (2001) Alternative splicing of the human VEGFGR-3/FLT4 gene as a 
consequence of an integrated human endogenous retrovirus. J.Mol.Evol. 53: 
77-79. 
Huhtaniemi I. & Toppari J. (1995) Endocrine, paracrine and autocrine regulation of 
testicular steroidogenesis. Adv.ExpMed.Biol. 377: 33-54. 
Hutson J. C. (1994) Testicular macrophages. Int.Rev.CytoL 149: 99-143. 
Jackson C. M. & Jackson H. (1984) Comparative protective actions of gonadotrophins 
and testosterone against the antispermatogenic action of ethane 
dimethanesulphonate. J.i^e/jro^/.Ferr//. 71: 393-401. 
Jegou B. & Pineau C. (1995) Current aspects of autocrine and paracrine regulation of 
spermatogenesis. Adv.ExpMed.Biol 377: 67-86. 
joukov V.’ Pajusola K.，Kaipainen A.’ Chilov D.，Lahtinen 1.，Kukk E.，Saksela O.’ 
Kalkkinen N.，& Alitalo K. (1996) A novel vascular endothelial growth factor, 
VEGF-C, is，a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor 
tyrosine kinases. EMBO J. 15: 290-298. 
Joukov V.，Sorsa T.’ Kumar V.，Jeltsch M.，Claesson-Welsh L.’ Cao Y.，Saksela 0 ” 
Kalkkinen N.’ & Alitalo K. (1997a) Proteolytic processing regulates receptor 
specificity and activity of VEGF-C. EMBO J. 16: 3898-3911. 
139 
Joukov v . , Ka ipa inen A., Jel tsch M.，Pajusola K.，Olofsson B.，Kumar V.，Eriksson U.，& 
Alitalo K. (1997b) Vascular endothelial growth factors VEGF-B and VEGF-C. 
J.Cell Physiol 
Joukov v . , K u m a r V.，Sorsa T.，Arighi E.，Weich H.，Saksela 0 ” & Mi ta lo K. (1998) A 
recombinant mutant vascular endothelial growth factor-C that has lost vascular 
endothelial growth factor receptor-2 binding, activation，and vascular permeability 
activities. J.BioLChem. 273: 6599-6602. 
Kaipainen A., Korhonen J.，Mustonen T.，van Hinsbergh V. W.，Fang G. H.，Dumont D.， 
Breitman M.，& Alitalo K. (1995) Expression of the fins-like tyrosine kinase 4 gene 
becomes restricted to lymphatic endothelium during development. 
Proc.Natl.Acad.Sci.U.S.A 92: 3566-3570. 
Kendall R. L.，Wang G .，& Thomas K. A. (1996) Identification of a natural soluble form 
of the vascular endothelial growth factor receptor, FLT-1, and its 
heterodimer iza t ion wi th K D R . Biochem.Biophys卫es.Commun. 226: 324-328. 
Kem S.，Robertson S. A.，Mau V. J., & Maddocks S. (1995) Cytokine secretion by 
macrophages in the rat testis. Biol.Reprod. 53: 1407-1416. 
Kerr J. B. & Sharpe R. M. (1989) Macrophage activation enhances the human chorionic 
gonadot rophin- induced disruption o f spermatogenesis in the rat. J.Endocrinol 121: 
285-292. 
Ko W. H .，A u C. L . ， & Y i p C. Y. (2003) Multiple purinergic receptors lead to 
intracellular calcium increases in cultured rat Sertoli cells. Life ScL 72: 1519-1535. 
Korpe la inen E. I., Karkka inen M . J., Tenhunen A.，Lakso M.，Rauvala H., V iemla M., 
Parvinen M.，& Alitalo K. (1998) Overexpression of VEGF in testis and epididymis 
causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF. 
J.Cell Biol. 143: 1705-1712. 
140 
Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V.，& Alitalo K. 
(1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 
suggests a role in lymphatic vascular development. Development 122: 3829-3837. 
Laitinen M:’ Ristimaki A., Honkasalo M.，Narko K.，Paavonen K.，& Ritvos O. (1997) 
Differential hormonal regulation of vascular endothelial growth factors VEGF, 
VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human 
granulosa-luteal cells. Endocrinology 138: 4748-4756. 
Laslett A. L.，McFarlane J. R.，& Risbridger G. P. (1997) Developmental response by 
Leydig cells to acidic and basic fibroblast growth factor. J.Steroid 
BiochemMolBiol 60: 171-179. 
Lee J” Gray A., Yuan J., Luoh S. M.，Avraham H., & Wood W. 1. (1996) Vascular 
endothelial growth factor-related protein: a ligand and specific activator of the 
tyrosine kinase receptor Flt4. Pwc.Natl.Acad.ScL U.S.A 93: 1988-1992. 
Lei J., Jiang A.，& Pei D. (1998) Identification and characterization of a new splicing 
variant of vascular endothelial growth factor: VEGF183. Biochim.Biophys.Acta 
1443: 400-406. 
Leung D. W., Cachianes G.’ Kuang W. J., Goeddel D. V.’ & Ferrara N. (1989) Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science 246: 
1306-1309. 
Li X. & Eriksson U. (2001) Novel VEGF family members: VEGF-B, VEGF-C and 
VEGF-D. IntJ.Biochem.CellBioL 33: 421-426. 
Lopez J. J., Laham R. J.，Carrozza J. P., Tofukuji M.，Sellke F. W.，Bunting S., & Simons 
M. (1997) Hemodynamic effects of intracoronary VEGF delivery: evidence of 
tachyphylaxis and NO dependence of response. AmJ.Physiol 273: H1317-H1323. 
141 
Maglione D.’ Guerriero V., Viglietto G.，Delli-Bovi P., & Persico M. G. (1991) Isolation 
of a human placenta cDNA coding for a protein related to the vascular permeability 
factor. Proc.Natl.Acad.Sci.U.S.A 88: 9267-9271. 
Maglione D.，Guerriero V.，Viglietto G.，Ferraro M. G., Aprelikova O., Alitalo K.，Del 
Vecchio S.，Lei K. J., Chou J. Y.，& Persico M. G. (1993) Two alternative mRNAs 
coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed 
from a single gene of chromosome 14. Oncogene 8: 925-931. 
Makinen T.，Olofsson B.，Karpanen T.，Hellman U.，Soker S.，Klagsbrun M., Eriksson U., 
& Alitalo K. (1999) Differential binding of vascular endothelial growth factor B 
splice and proteolytic isoforms to nemopilin-l. J.Biol.Chem. 274: 21217-21222. 
Marconcini L.，Marchio S.，Morbidelli L.，Cartocci E.，Albini A.，Ziche M., Bussolino F.， 
& Oliviero S. (1999) c-fos-induced growth factor/vascular endothelial growth 
factor D induces angiogenesis in vivo and in vitro. Proc.Natl.Acad.Sci.U.S.A 96: 
9671-9676. 
Matthews W.，Jordan C. T.，Gavin M.’ Jenkins N. A” Copeland N. G., & Lemischka 1. R. 
(1991) A receptor tyrosine kinase cDNA isolated from a population of enriched 
primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. 
Proc.NatlAcad.ScLU.SA 88: 9026-9030. 
McLachlan R. I.，Wreford N. G.，Meachem S. J., de Kretser D. M.，& Robertson D. M. 
(1994) Effects of testosterone on spermatogenic cell populations in the adult rat. 
Biol.Reprod. 51: 945-955. 
Mendelson C.，Dufau M.，& Catt K. (1975) Gonadotropin binding and stimulation of 
cyclic adenosine 3':5'-monophosphate and testosterone production in isolated 
Leydig CQWS. J.Biol.Chem. 250: 8818-8823. 
142 
Migdal M. , Huppe r t z B. , Tessler S.，Comforti A.，Shibuya M.，Reich R.，Baumann H.，& 
Neufeld G. (1998) Neuropilin-1 is a placenta growth factor-2 receptor. J.BiolChem. 
273: 22272-22278. 
Murono E. P., Washburn A. L.，Goforth D. P., & Wu N. (1992) Evidence for basic 
fibroblast growth factor receptors in cultured immature Leydig cells. MolCell 
Endocrinol 88: 39-45. 
Neufeld G.，Cohen T., Gengrinovitch S.，& Poltorak Z. (1999) Vascular endothelial 
growth factor (VEGF) and its receptors. FASEB J. 13: 9-22. 
Neulen J., Raczek S.，Pogorzelski M.，Gmnwald K.，Yeo T. K.，Dvorak H. F.，Weich H. 
A., & Breckwoldt M. (1998) Secretion of vascular endothelial growth 
factor/vascular permeability factor from human luteinized granulosa cells is human 
chorionic gonadotrophin dependent. MolHum.Reprod. 4: 203-206. 
Ni Y.，May V.，Braas K .，& Osol G. (1997) Pregnancy augments uteroplacental vascular 
endothelial growth factor gene expression and vasodilator effects. AmJ.Physiol 273: 
H938-H944. 
Niemi M., Sharpe R. M., & Brown W. R. (1986) Macrophages in the interstitial tissue of 
the rat testis. Cell Tissue Res. 243: 337-344. 
Norrby K. (1997) Angiogenesis: new aspects relating to its initiation and control. APMIS 
105:417-437. 
Olofsson B” Pajusola K.，Kaipainen A” von Euler G” Joukov V., Saksela 0 ” Orpana A., 
Pettersson R. F.，Alitalo K., & Eriksson U. (1996a) Vascular endothelial growth 
factor B, a novel growth factor for endothelial cells. Proc.Natl.Acad.Sci.U.S.A 93: 
2576-2581. 
143 
Olofsson B.，Pajusola K.，von Euler G.，Chilov D.，Alitalo K .，& Eriksson U. (1996b) 
Genomic organization of the mouse and human genes for vascular endothelial 
growth factor B (VEGF-B) and characterization of a second splice isoform. 
J.Biol. Chem. 271: 19310-19317. 
Olofsson B.，Korpelainen E.，Pepper M. S., Mandriota S. J” Aase K., Kumar V., Gunji Y.， 
Jeltsch M. M., Shibuya M.，Alitalo K., & Eriksson U. (1998) Vascular endothelial 
growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen 
activator activity in endothelial cells. Proc.Natl.Acad.Sci. U.S.A 95: 11709-11714. 
Olofsson B.，Jeltsch M.，Eriksson U.，& Alitalo K. (1999) Current biology of VEGF-B 
and VEGF-C. Curr.Opin.Biotechnol 10: 528-535. 
Orlandini M.，Marconcini L.，Ferruzzi R.’ & Oliviero S. (1996) Identification of a 
c-fos-induced gene that is related to the platelet-derived growth factor/vascular 
endothelial growth factor family. Proc.Natl.Acad.Sci. U.S.A 93: 11675-11680. 
Pajusola K.，Aprelikova O.，Korhonen J.，Kaipainen A., Pertovaara L.，Alitalo R.，& 
Alitalo K. (1992) FLT4 receptor tyrosine kinase contains seven 
immunoglobulin-like loops and is expressed in multiple human tissues and cell 
lines. Cancer Res. 52: 5738-5743. 
Pajusola K., Aprelikova 0 ” Armstrong E.，Morris S” & Alitalo K. (1993) Two human 
FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are 
produced by alternative processing of primary transcripts. Oncogene 8: 2931-2937. 
Pajusola K.，Aprelikova O.，Pelicci G.，Weich H.，Claesson-Welsh L., & Alitalo K. (1994) 
Signalling properties of FLT4，a proteolytically processed receptor tyrosine kinase 
related to two VEGF receptors. Oncogene 9: 3545-3555. 
Park J. R , Chen H. H.，Winer J.，Houck K. A” & Ferrara N. (1994) Placenta growth 
factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in 
144 
vivo, and high affinity binding to Flt-1 but not to Flk-l/KDR. J.Biol.Chem. 269: 
25646-25654. 
Partanen T. A.，Arola J.，Saaristo A.，Jussila L.，Ora A., Miettinen M., Stacker S. A., 
Achen M. G.，& Alitalo K. (2000) VEGF-C and VEGF-D expression in 
neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in 
human tissues. FASEB J. 14: 2087-2096. 
Pepper M. S. (1997) Manipulating angiogenesis. From basic science to the bedside. 
Arterioscler. Thromb. Vasc.Biol 17: 605-619. 
Poltorak Z.，Cohen T.，Sivan R., Kandel is Y.，Spira G., Vlodavsky I.，Keshet E.，& 
Neufeld G. (1997) VEGF 145，a secreted vascular endothelial growth factor isoform 
that binds to extracellular matrix. J.Biol.Chem. 272: 7151-7158. 
Poltorak Z.，Cohen T.，& Neufeld G. (2000) The VEGF splice variants: properties, 
receptors, and usage for the treatment of ischemic diseases. Herz 25: 126-129. 
Ristimaki A., Narko K.，Enholm B.，Joukov V.，& Alitalo K. (1998) Proinflammatory 
cytokines regulate expression of the lymphatic endothelial mitogen vascular 
endothelial growth factor-C. J.Biol.Chem. 273: 8413-8418. 
Robaire B.’ Ewing L. L.，Irby D. C.，& Desjardins C. (1979) Interactions of testosterone 
and estradiol-17 beta on the reproductive tract of the male rat. Biol.Reprod. 21: 
455-463. 
Robinson C. J. & Stringer S. E. (2001) The splice variants of vascular endothelial growth 
factor (VEGF) and their receptors. J.Cell ScL 114: 853-865. 
Rulli S. B.，Ahtiainen P., Makela S.，Toppari J.’ Poutanen M.，& Huhtaniemi 1. (2003) 
Elevated steroidogenesis, defective reproductive organs, and infertility in 
145 
transgenic male mice overexpressing human chorionic gonadotropin. 
Endocrinology 144: 4980-4990. 
Ruohola J. K.，Valve E. M., Karkkainen M. J., Joukov V.，Alitalo K.，& Harkonen P. L. 
(1999) Vascular endothelial growth factors are differentially regulated by steroid 
hormones and antiestrogens in breast cancer cells. Mol.Cell Endocrinol 149: 
29-40. 
Saaristo A., Partanen T. A.，Arola J., Jussila L.，Hytonen M., Makitie A., Vento S.， 
Kaipainen A., Malmberg H.，& Alitalo K. (2000) Vascular endothelial growth 
factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal 
tumors. Am J.Pathol 157: 7-14. 
Sandner P., Wolf K.，Bergmaier U.，Gess B.，& Kurtz A. (1997) Induction of VEGF and 
VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in 
vitro. Kidney Int. 51: 448-453. 
Sawano A., Takahashi T.，Yamaguchi S.，Aonuma M” & Shibuya M. (1996) Flt-1 but not 
KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related 
to vascular endothelial growth factor. Cell Growth Differ. 7: 213-221. 
Schiffenbauer Y. S.，Abramovitch R.，Meir G.，Nevo N., Holzinger M” Itin A.，Keshet E., 
& Neeman M. (1997) Loss of ovarian function promotes angiogenesis in human 
ovarian carcinoma. Proc.Natl.Acad.Sci.U.S.A 94: 13203-13208. 
Seetharam L.，Gotoh N.’ Mam Y.’ Neufeld G.，Yamaguchi S., & Shibuya M. (1995) A 
unique signal transduction from FLT tyrosine kinase, a receptor for vascular 
endothelial growth factor VEGF. Oncogene 10: 135-147. 
Setchell B. P. (1978) Vascular supply and drainage of the testis. In: The Mammalian 
Testis pp. 50-76. Elek Books, London. 
146 
Setchell B. P. & Sharpe R. M. (1981) Effect of injected human chorionic gonadotrophin 
on capillary permeability, extracellular fluid volume and the flow of lymph and 
blood in the testes of rats. J.Endocrinol 91: 245-254. 
Setchell B. P. & Rommerts F. F. (1985) The importance of the Leydig cells in the 
vascular response to hCG in the rat testis. IntJ.Androl 8: 436-440. 
Setchell B. P., Maddocks S., & Brooks D. E. (1994) Anatomy, vasculature, innervation, 
and fluids of the male repoductive tract. In: The Physiology of Reproduction, 2nd 
Edition (eds E. Knobil and J. D. Neill) pp. 1063-1175. Raven Press, New York. 
Shalaby F.，Rossant J., Yamaguchi T. P., Gertsenstein M.，Wu X. R, Breitman M. L., & 
Schuh A. C. (1995) Failure of blood-island formation and vasculogenesis in 
Flk-1-deficient mice. Nature 376: 62-66. 
Shibuya M., Yamaguchi S.，Yamane A., Ikeda T., Tojo A” Matsushime H.，& Sato M. 
(1990) Nucleotide sequence and expression of a novel human receptor-type 
tyrosine kinase gene (fit) closely related to the fins family. Oncogene 5\ 519-524. 
Shibuya M.， I to N .， & Claesson-Welsh L. (1999) Structure and function of vascular 
endothelial growth factor receptor-l and -2. Curr.Top.MicrobioUmmunol. 237: 
59-83. 
Shima D. T.，Kuroki M.，Deutsch U.，Ng Y. S” Adamis A. P., & D’Amore P. A. (1996) 
The mouse gene for vascular endothelial growth factor. Genomic structure, 
definition of the transcriptional unit, and characterization of transcriptional and 
post-transcriptional regulatory sequences. J.BiolChem. 271: 3877-3883. 
Shweiki D•，Itin A.，Soffer D.，& Keshet E. (1992) Vascular endothelial growth factor 
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 
843-845. 
147 
Shweiki D.，Itin A., Neufeld G., Gitay-Goren H., & Keshet E. (1993) Patterns of 
expression of vascular endothelial growth factor (VEGF) and VEGF receptors in 
mice suggest a role in hormonally regulated angiogenesis. J.Clin.Invest 91: 
2235-2243. 
Soker S.，Takashima S.，Miao H. Q.，Neufeld G.，& Klagsbmn M. (1998) Neuropilin-1 is 
expressed by endothelial and tumor cells as an isoform-specific receptor for 
vascular endothelial growth factor. Cell 92: 735-745. 
Sugihara T.，Wadhwa R., Kaul S. C., & Mitsui Y. (1998) A novel alternatively spliced 
form of murine vascular endothelial growth factor, VEGF 115. J.Biol.Chem. 273: 
3033-3038. 
Sun X. R. & Risbridger G. P. (1994) Site of macrophage inhibition of luteinizing 
hormone-stimulated testosterone production by purified leydig cells. Biol.Reprod. 
50: 363-367. 
Sun Y. T.，Irby D. C.，Robertson D. M .， & de Kretser D. M. (1989) The effects of 
exogenously administered testosterone on spermatogenesis in intact and 
hypophysectomized rats. Endocrinology 125: 1000-1010. 
Terman B. I.，Carrion M. E.，Kovacs E.，Rasmussen B. A.，Eddy R. L., & Shows T. B. 
(1991) Identification of a new endothelial cell growth factor receptor tyrosine 
kinase. Oncogene 6: 1677-1683. 
Terman B. I.，Dougher-Vermazen M., Carrion M. E.，Dimitrov D.，Armellino D. C.， 
Gospodarowicz D.’ & Bolilen P. (1992) Identification of the KDR tyrosine kinase 
as a receptor for vascular endothelial cell growth factor. 
Biochem.Biophys.Res.Commun. 187: 1579-1586. 
148 
Tilton R. G.，Chang K. C.，LeJeune W. S.，Stephan C. C.，Brock T. A., & Williamson J. R. 
(1999) Role for nitric oxide in the hyperpermeability and hemodynamic changes 
induced by intravenous VEGF. Invest Ophthalmol. Vis.Sci. 40: 689-696. 
Toi M.，Inada K.，Hoshina S” Suzuki H., Kondo S” & Tominaga T. (1995) Vascular 
endothelial growth factor and platelet-derived endothelial cell growth factor are 
frequently coexpressed in highly vascularized human breast cancer. Clin. Cancer 
Res. 1:961-964. 
Vailhe B.，Vittet D.，& Feige J. J. (2001) In vitro models of vasculogenesis and 
angiogenesis. Lab Invest 81: 439-452. 
Veikkola T. & Alitalo K. (1999) VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 
9:211-220. 
Waltenberger J.，Claesson-Welsh L.，Siegbahn A., Shibuya M., & Heldin C. H. (1994) 
Different signal transduction properties of KDR and Fltl，two receptors for 
vascular endothelial growth factor. J.BioLChem. 269: 26988-26995. 
Wang H., Ascoli M., & Segaloff D. L. (1991) Multiple luteinizing hormone/chorionic 
gonadotropin receptor messenger ribonucleic acid transcripts. Endocrinology 129: 
133-138. 
Wen Y.，Edelman J. L.，Kang T” Zeng N.，& Sachs G. (1998) Two functional forms of 
vascular endothelial growth factor receptor-2/Flk-l mRNA are expressed in normal 
v^tvQim^. J.BioLChem. 273: 2090-2097. 
Widmark A., Damber J. E.，& Bergh A. (1986) Relationship between human chorionic 
gonadotrophin-induced changes in testicular microcirculation and the formation of 
testicular interstitial fluid. J.Endocrinol 109: 419-425. 
149 
Winther H.，Ahmed A., & Dantzer V. (1999) Immunohistochemical localization of 
vascular endothelial growth factor (VEGF) and its two specific receptors，Flt-1 and 
KDR, in the porcine placenta and non-pregnant uterus. Placenta 20: 35-43. 
Woodruff T. K.，Borree J., Attie K. M., Cox E. T.，Rice G. C .，& Mather J. P. (1992) 
Stage-specific binding of inhibin and activin to subpopulations of rat germ cells. 
Endocrinology 130: 871-881. 
Wulff C.，Dickson S. E.，Duncan W. C.，& Fraser H. M. (2001) Angiogenesis in the 
human corpus luteum: simulated early pregnancy by HCG treatment is associated 
with both angiogenesis and vessel stabilization. Hum.Reprod. 16: 2515-2524. 
Y a m a n e A.，Seetharam L.，Yamaguchi S.，Gotoh N ” Takahashi T.，Neufeld G.，& 
Shibuya M. (1994) A new communication system between hepatocytes and 
sinusoidal endothelial cells in liver through vascular endothelial growth factor and 
Fit tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 9: 2683-2690. 
Yamada Y.，Nezu J., Shimane M .， & Hirata Y. (1997) Molecular cloning of a 丽 e l 
vascular endothelial growth factor, VEGF-D. Genomics 42: 483-488. 
Yee J. B. & Hutson J. C. (1985) Effects of testicular macrophage-conditioned medium on 
Leydig cells in culture. Endocrinology 116: 2682-2684. 
Yoshida A., Anand-Apte B.，& Zetter B. R. (1996) Differential endothelial migration and 
proliferation to basic fibroblast growth factor and vascular endothelial growth 
factor. Growth Factors 13: 57-64. 
Zheng W. X.，Butwell T. J., Heckert L.，Griswold M. D.，& Bellve A. R. (1990) 
pieiotypic actions of the seminiferous growth factor on two testicular cell lines: 




CUHK L i b r a r i e s 
_ _ _ _ 
